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Despite the success of traditional cancer treatments, a definite cure to several can-
cers does not exist. Further, the traditional cancer treatments are highly toxic
and have a relatively low efficacy. Current research and clinical trials have in-
dicated that virotherapy, a procedure which uses replication-competent viruses
to kill cancer cells, is less toxic and highly effective. Some recent studies suggest
that the success of combating cancer lies in the understanding of tumour-immune
interactions. However, the interaction dynamics of recent cancer treatments with
the tumour and immune system response are still poorly understood.
In this thesis we construct and analyse mathematical models in the form of or-
dinary and partial differential equations in order to explain tumour invasion dy-
namics and new forms of cancer treatment. We use these models to suggest
possible measures needed in order to combat cancer. The thesis seeks to deter-
mine the most critical biological factors during tumour invasion, describe how the
virus and immune system response influences the outcome of oncolytic virother-
apy treatment, investigate how drug infusion methods determine the success of
chemotherapy and virotherapy, and determine the efficacy of chemotherapy and
virotherpy in depleting tumour cells from body tissue.
We present a travelling wave analysis of a tumour-immune interaction model with
immunotherapy. Here we aim to investigate the existence of travelling wave solu-
tions of the model equations with and without immunotherapy and calculate the
iii
minimum wave speed with which tumour cells invade healthy tissue. This inves-
tigation highlights the properties which are most vital during tumour invasion.
We use the geometric treatment of an apt-phase space to establish the intersection
between stable and unstable manifolds. Numerical simulations are performed
to support the analytical results. The analysis reveals that the main factors in-
volved during tumour invasion include the tumour growth rate, resting immune
cell growth rate, carrying capacity of the resting immune cells, resting cell supply,
diffusion rate of the tumour cells, and the local kinetic interaction parameters. We
also present a mathematical analysis of models that study tumour-immune-virus
interactions using differential equations with spatial effects. The major aim is to
investigate how virus and immune responses influence the outcome of oncolytic
treatment. Stability analysis is carried out to determine the long term behaviour
of the model solutions. Analytical traveling wave solutions are obtained using
factorization of differential operators and numerical simulations are carried out
using Runge-Kutta fourth order method and Crank-Nicholson methods. Our re-
sults show that the use of viruses as a means of cancer treatment can reduce the
tumour cell concentration to a very low cancer dormant state or possibly erad-
icate all tumour cells in body tissue. The traveling wave solutions indicate an
exponential increase and decrease in the immune cells density and tumour load
in the long term respectively.
A mathematical model of chemovirotherapy, a recent experimental treatment
which combines virotherapy and chemotherapy, is constructed and analyzed. The
aim is to compare the efficacy of three drug infusion methods and predict the
outcome of oncolytic virotherapy-drug combination. A comparison of the effi-
cacy of using each treatment individually, that is, chemotherapy and virotherapy,
is presented. Analytical solutions of the model are obtained where possible and
stability analysis is presented. Numerical solutions are obtained using the Runge-
Kutta fourth order method. This study shows that chemovirotherapy may have a
iv
higher chance of reducing the tumour cell density in body tissue in a relatively
short time. To the best of our knowledge, there has not been a mathematical study
on the combination of both chemotherapy and virotherapy.
Lastly, the chemovirotherapy model is extended to include spatial distribution
characteristics, thus developing a model which describes avascular tumour growth
under chemovirotherapy in a two dimensional spatial domain. Numerical inves-
tigation of the model solutions is carried out using a multi domain monomial
based collocation method and pdepe, a finite element based method in Matlab.
This study affirmed that chemovirotherapy may possibly eradicate all tumour
cells in body tissue.
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1.1 Background and motivation
Cancer, known medically as a malignant tumour, is currently the third leading
cause of death in the world, after cardiovascular and infectious diseases (see Refs
[1–3]). The National Vital Statistics Report [1] ranks neoplasms of the trachea,
bronchus, and lung cancer as some of the most dangerous cancers and leading
causes of death. The 2014 World Health Organization Cancer Report [4] states
that 8.2 million people die each year from cancer, which is about 13% of all deaths
worldwide.
Cancer begins when body tissue cells grow uncontrollably to form a solid tis-
sue mass, known as a tumour, which later becomes invasive. Solid tumours are
mainly caused by genetic disorders, tobacco and alcohol abuse, poor diet and
physical inactivity, and radiation exposure among other carcinogens [5]. There
are over one hundred distinct cancer types with diverse dynamics [6]. The partic-
ular cancer type is usually reflected by the tissue in which it arises, for example,
gliomas arise from the nervous system; carcinomas result from epithelial cells,
and meningiomas from the meninges.
1
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A human body is made up of cells of different types. These cells are subjected to
signals which determine their division, differentiation or death. If the cell mul-
tiplication is uncontrolled, for reasons mostly originating from altered Deoxyri-
bonucleic acid (DNA) sequences, this may lead to the formation of a spherical
cell mass. This mass can grow and expand, and can move to other body locations
through a process called metastasis, thus becoming cancerous. A tumour devel-
ops through two stages; the avascular and vascular growth stages. The avascular
stage is the first phase during which cells replicate uncontrollably. These cells,
after contracting in one place, require oxygen and other essential nutrients for
further growth. In the search for these nutrients they sprout out blood vessels to
surrounding body tissue, thus moving to other body parts through two processes;
angiogenesis and metastasis, which form the second stage of tumour growth [7].
During angiogenesis, tumour cells secrete biological signals known as tumour an-
giogenetic factors (TAF) which attract blood vessels towards the tumour to supply
unlimited nutrients. Tumour cells can then move into the blood stream and settle
in other body parts, a process known as metastasis. In this thesis and for all the
models, we consider avascular solid tumours prior to angiogenesis.
A solid tumour consists of three layers: the necrotic core which contains cells
deprived of nutrients, a quiescent layer which contains nascent cells, and a zone
containing cells lying at the sheath of the tumour. The sheath of a tumour con-
tains fast proliferating cells. Nascent cells lying in the quiescent layer may either
die and move to the center of the tumour to form the necrotic core or may later
be recruited into the proliferating zone [8]. A tumour may however remain dor-
mant without metastasizing, possibly for an entire life time. This is supported by
clinical evidence by Aguirre-Ghiso [9] and some mathematical models (see, for
example, [10, 11] and the references cited therein). Current research attributes
this dormancy to the interactions of immune cells with tumour cells (see [10, 11]).
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Mambili-Mamboundou et al. [11] showed using a mathematical analysis that tu-
mour infiltarating cytotoxic lymphocytes (TICLs) are capable of reducing tumour
cell density to a very low and dormant state, but may not completely eliminate
these cells.
Tumour cells have mechanisms through which they elude the immune system
surveillance. These include: immune inactivation by tumour-derived cytokines;
macrophage migration inhibitory factors (MIF) blocks T-cells activation and in-
duces their death [12], immunosupression through amino acid depletion, accu-
mulation of tumour regulation T cells (Tregs) [13], resistance to apoptosis, and
immune inactivation by tumour derived cytokines [14]. It is therefore virtually
impossible to mitigate tumour growth without any form of clinical therapy.
Cancer therapies are as diverse as cancer itself. The function of all cancer treat-
ments however is to destroy cancer cells and should also distinguish between can-
cerous and healthy cells. Traditional cancer treatment methods include chemother-
apy (see for example [15–20]) , surgical methods (see for example [21–24] ), and
radiation therapy (see for example [25–27]). Modern cancer therapies include
imunotherapy (see for example [28–31]), use of anti-angiogenic drugs (see for ex-
ample [32, 33]), and virotherapy (see for example [10, 34–37]). Here we give a
review of chemotherapy, immunotherapy and virotherapy as they are the most
relevant to the aims of this study.
Chemotherapy involves the use of drugs which are administered orally or intra-
venously to directly lyse cancer cells. These drugs target fast multiplying cells,
thus utilizing the fact that cancer cells are fast replicating and hindering their
ability to grow. Many of these drugs have the ability to interfere with the syn-
thesis of molecules needed for DNA replication. They may accomplish this in
several ways, for example, they can hinder the cell from completing the S phase
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of the cell cycle. Some drugs like antitumour antibiotics, bind to the cell DNA to
interfere with DNA replication and transcription. A class of drugs inhibits cell
replication during mitosis. During this stage of cell growth chromosome sepa-
ration requires spindle fibers which are made of microtubules; spindle inhibitors
prevent the synthesis of microtubules [38, 39]. Because chemotherapeutic drugs
lyse fast multiplying cells, they also kill certain cells that divide rapidly such as
hair follicles, cells in the gastrointestinal tract, and bone marrow cells thus caus-
ing dangerous side effects which include severe hair loss, low white blood cell
count, and gastrointestinal distress [38].
Immunotherapy involves boosting a body’s immune system to mitigate cancer
growth. There are three categories of immunotherapy: the use of immune boost-
ing substances, use of monoclonal antibodies, and the use of vaccines. In the
first category, non-specific immunotherapies for example, laboratory made in-
terleukines and interferons are injected in a human body to boost the immune
system thus lysing or slowing down the growth of cancer cells. Most non-specific
immunotherapies are administered in combination with other treatments, for ex-
ample, chemotherapy [40]. The second category involves monoclonal antibodies
which are directed against a specific protein in cancer cells. Once a monoclonal
antibody attaches to a cancer cell, it may allow for the immune system to destroy
it or prevent it from rapidly growing. Some monoclonal antibodies direct drugs
to the cancer cells, for example, Brentuximab vedotin (Adcetris), a cancer therapy
for certain Hodgkin types and non-Hodgkin lymphoma [40]. Other monoclonal
antibodies which are currently in use for cancer treatments include recombinant
DNA-derived humanized IgG1 kappa monoclonal antibody (Alemtuzumab), Be-
vacizumab, Cetuximab, Ipilimumab, and Nivolumab. Several others are under
clinical trials. The use of monoclonal antibodies can also be classified as a form
of targeted therapy where they are used to target tumour cell specific genes, pro-
teins, or the tissue environment that contributes to cancer growth [40]. In the third
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category, vaccines are used to expose the immune system to antigens thus trigger-
ing the immune system to recorgnize and destroy the protein or related materials.
There are two major types of vaccines: preventive vaccines which are given to a
person with no cancer symptoms to prevent the person from developing a specific
cancer type, for example, Gardasil and Cervarix are vaccines that prevent infec-
tion from human papillomavirus (HPV), and treatment vaccine which helps the
body’s immune system fight cancer by instructing it to recognize and lyse cancer
cells [40]. Immunotherapy side effects include low blood pressure, rashes, and
flu-like symptoms, such as fever. In this study we consider only the first category
where a laboratory made protein, specifically interleukine2 (IL2), is injected into
a human body to stimulate the immune system thus boosting its response to the
growth of cancer cells.
Virotherapy involves the conversion of certain viruses into cancer-fighting agents
by engineering them to directly attack cancerous cells, while normal healthy cells
remain undamaged. The idea of using viruses as a treatment for cancer began
in the 1950s, when tissue culture and rodent cancer models were originally de-
veloped [41]. Oncolytic treatment involves the use of virus genomes which are
altered to greatly enhance their anti-tumour specificity. This began with a study
in which thymidine Kinase-negative HSV with attenuated neurovirulence was
shown to be active in a murine glioblastoma model. Since then, the pace of clinical
activities has accelerated considerably, with several trials using oncolytic viruses
belonging to different virus families [10]. To date, several viruses have been de-
veloped, for example, adenovirus which has been approved in China [42], and
Newcastle-disease virus (NDV) which are in phase three of clinical trials [43].
There is no recorded toxicity as a result of clinical use of oncolytic virotherapy
to treat cancer [10, 34–37]). The virus characteristics that are most important in
increasing the efficacy of virotherapy treatment are not well known despite the
magnitude of research which has been done so far. In this thesis we will highlight
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some of the most important virus characterisitcs which need to be optimized in
order to mitigate cancer growth in body tissue.
Despite the success of existing cancer therapies, a definite cure to several can-
cers does not exist. This is because tumours possess mechanisms that suppress
anti-tumour activity such as ligands that block natural killer cells and cytotoxic
tumour infiltrating cell functions [44]. Thus tumour cells disguise themselves as
normal body tissue cells, making it hard for them to be lysed. Moreover most of
the traditional cancer treatments are highly toxic. This is as a result of their lysis
characteristics, that is, killing fast multiplying cells, however certain normal body
cells are also fast replicating. There is a dire need to therefore investigate the effi-
cacy of new forms of cancer treatments that are less toxic, and determine tumour
invasion characteristics that should be targeted in order to eradicate tumour cells
from body tissue which could lead to a cancer cure.
1.2 A review of mathematical models
In this section we review mathematical models of tumour invasion dynamics and
cancer therapy. We also point out some studies in cancer research that are of
relevance in this thesis.
Mathematical modeling of tumours and their macro environment have been stud-
ied since the early 1980’s (see for example [45]). Differential equations as tools of
modeling have since been employed to draw very important deductions in can-
cer dynamics and therapy. The major results which have thus far been drawn
from the analysis of these models, according to d’Onfrio et al. [46], include; the
existence of a tumour free equilibrium, the possibility of a tumour growing to
maximum size, the possibility of co-existence of a tumour, in small concentra-
tions with immune cells (see for example [11]), limit cycles, where the tumour
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and immune cell concentrations can keep alternating in a repetitive manner (see
for example [47]), and a constant influx of immune cells in the tumour localiza-
tion. Cancer treatment models, using differential equations have also since been
developed and analyzed (see for example the models in [48]).
Mambili-Mamboundou et al. [11] presented a tumour-immune interaction model
with immunotherapy to investigate cancer dormancy, a scenario where a tumour
remains dormant for several years. Their model divided the cell population into
concentrations of primed tumour infiltrating cytotoxic lymphocytes (TICLs), tu-
mour cells , interleukine2, a cell complex, a chemokine , and resting cells. They
assumed that the IL2 does not bind with TICLs to form a cell complex but instead
stimulates the immune system response against tumour cells through lymphocyte
activation, growth, and differentiation. The model was an extension of Matzavi-
nos et al. [47] with the inclusion of a class of resting cells and the assumption
that the formation of the cell complexes occurs on a time scale of a few hours,
while that of tumour cells as well as the influx of immune cells into the spleen
occurs on a much slower time scale. They extended this model to incorporate
space and thus studied the tumour-immune spatial temporal dynamics. The ho-
mogeneous model was analyzed through a stability analysis and numerical sim-
ulations and the heterogeneous model was simulated using the Crank-Nicholson
scheme. Their analysis showed that immune cells are capable of keeping the
tumour cell concentration at low levels and for a long period of time but may
not totally eliminate them. The spatial model simulations showed oscillations
in densities of both TICLs and the tumour with the tumour cell density having
a small amplitude compared to the TICLs. The analysis also revealed that im-
munotherapy may reduce the tumour cell density inside the body tissue. Despite
the fact that these results are helpful in explaining cancer dormancy, they did
not explain the most important tumour invasion parameters. Furthermore, a dor-
mant tumour may metastasize [49]. It is therefore important to investigate the
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pertinent mechanisms, that is parameters in mathematics, through which tumour
cells escape the immune system surveillance. Other studies of tumour dynamics
and immunotherapy include the following research [45, 47, 50–54]. These stud-
ies give an indication of some important issues pertaining to cancer dynamics.
Nevertheless, the dynamics of tumour-immune interactions are highly intricate
and involve many parameters and therefore, there is a need for more studies to
decode the mechanisms of tumour-immune interaction as this could potentially
reveal another avenue of determining a cure for cancer.
Phino et al. [55] developed a mathematical model of chemotherapy for treatment
of a tumour with the aim of investigating the efficacy of chemotherapy in elimi-
nating cancer cells. In their analysis they showed the region of parameter space
in which cancer cells can be eliminated. They also showed the outcome of the
cell concentrations with varying infusion rates of the drug. Other chemotherapy
mathematical models include [55–58]. Ursher [48] gave a comprehensive sum-
mary of mathematical models for chemotherapy. The analysis of all these models
do not point to chemotherapy as a global cure for cancer. Therefore, there is a
need to study new cancer treatment forms and combinations.
Tian [59] constructed and analyzed a basic mathematical model of virotherapy. He
considered populations of uninfected tumour cells, infected tumour cells, and free
viruses. His analysis showed that there are two threshold burst size values: below
one of these values the tumour always grows to its maximum size, while above the
other value, there exists one or three families of periodic solutions arising from
Hopf bifurcations. His study confirmed that a tumour can be reduced to low
undetectable cell counts when the burst size is large enough. Similar virotherapy
mathematical models include [60–62].
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Mathematical models to simulate cancer treatment combinations are few in num-
ber, despite the large number of theoretical and experimental studies. Dingli et
al. [63] developed a mathematical model of cancer radiovirotherapy. They proved
the existence of steady states related to a complete success, partial success, and
therapy failure. They further evaluated the relevant therapeutic scenarios for the
treatment combinations and identified important elements of optimization. Tao
and Guo [64] described cancer radiovirotherapy using a free boundary problem
for a non-linear system of PDEs. They proved global existence and uniqueness
of the solutions to the boundary problem and constructed an explicit parame-
ter condition corresponding to the success of this therapy. To the best of our
knowledge, there has not been a mathematical study on the combination of both
chemotherapy and virotherapy, yet experimental studies have shown that the on-
colytic virotherapy (OV)-drugs combination may be a success in cancer treatment
(see Reference [65]). Therefore treatment outcomes of chemovirotherapy need to
be further investigated.
1.3 Classification of tumour dynamics models
There are several types of mathematical models, each requiring different tech-
niques of analysis. In this section we present a basic classification of tumour
dynamic models in mathematical biology, and appropriate to this thesis.
Mathematical tumour growth models may be categorized into microscopic and
macroscopic models. Microscopic models are based on observations on a micro-
scopic scale, for example, acidity, vascularization, and other internal cell dynam-
ics [66]. These models mostly incorporate observable chemical reactions between
tumour cells, the extra-cellular matrix and normal tissue cells, pressure, cell cohe-
sion, and adhesion. The chemical reactions include the diffusion of nutrients and
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oxygen into the tumour, mitosis, cell division, natural cell death, surface tension,
cell cycles, and chemotaxis. Consequently, there are several parameters involved
in such models and a large variety of mathematical techniques are a requirement
to analyze them. Some examples of microscopic models include those given in
[67–70] and the references therein.
Macroscopic models are based on observations on a macroscopic scale using,
for example, diffusion tensor images (MR-DTI), computed topography (CT), and
magnetic resonance images (MRI) [66]. The tumour dynamics observable fac-
tors on a macroscopic scale are limited and for this reason, macroscopic mod-
els are mathematically simple to analyze. The parameters that are most impor-
tant in macroscopic modeling include diffusion and chemotaxis. Examples of
macroscopic models can be found in the studies [11, 47, 50, 71, 72] and the refer-
ences therein. Malinzi [71] gives a further classification of tumour growth mod-
els. In this thesis we consider modeling on a macroscopic level with diffusion
and chemotaxis where necessary. We incorporate certain other salient features in
tumour growth modeling such as apoptosis, natural cell growth, and local cell
kinetic interactions.
The diffusion of cells, drugs, viruses, and other nutrients can be modeled using
the Fisher-Kolmogorov equation (see [73]). This equation can be used to model
the random movement of cells and nutrients in body tissue. The simplest macro-









) + ρU(1−U), (1.1a)
∇~n∂Ω = 0, (1.1b)
where U(x, t) is the cell density, D(x) is a space dependent function that models
the tumour diffusion coefficient. The function ρU(1−U) may be considered to be
the tumour density natural growth function where ρ is the tumour proliferation
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rate. Equation (1.1b) models the cell density at the boundaries of the tumour
(no-flux boundary condition). x and t are space and time variables.
In the context of this thesis, chemotaxis is the movement of cells in response to a
stimulus. The chemotaxis phenomenon can be simulated using the Patlak/Keler-












), t > 0, x ∈ Rd, (1.2)
where C(x, t) is the chemical density, χ represents the chemotactic sensitivity
function. The boundary conditions of Equation (1.2) depend on the assumptions
made pertaining to the movement of cells at the boundary of the tumour.
The mathematical models we construct in this thesis are in the form of ordinary
and partial differential equations. A differential equation relates a function with
its derivatives. The function simulates observable quantities in real life.
1.4 Aims of the study
Despite the fact that several mathematical studies on cancer treatments have been
conducted, more needs to be done in order to decode the complexities of the
underlying processes in tumour invasion. Striving to determine a cure for cancer
requires an investigation of processes such as the tumour invasion characteristics
and understanding the mechanisms of interaction of the immune system with
tumour cells. However, a full comprehension of tumour-immune interactions is
still lacking (see Ref [71]).
In recent studies, virotherapy, a less toxic treatment, has been identified as a
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possible cancer therapy (see [10, 41, 75]). This treatment type involves the use of
laboratory made oncolytic viruses that infect, multiply, and directly lyse cancer
cells with less toxicity [75]. The virus specific properties allow for biding, entry,
and fast replication in the tumour [65]. Nevertheless, little is known about the
virus characteristics that are most important for therapeutic purposes.
The major aim of this thesis is to investigate the efficacy of recent cancer treat-
ments and explain the phenomenon of cancer dormancy. This thesis seeks to
use analysis of mathematical models to achieve the following objectives: deter-
mine the most critical biological factors during tumour invasion, describe how the
virus and immune system response influences the outcome of oncolytic virother-
apy treatment, investigate how drug infusion methods determine the success of
chemotherapy and virotherapy, and determine the efficacy of chemotherapy and
virotherpy in depleting tumour cells from body tissue. Firstly, we seek to ob-
tain an estimate of the strength with which a tumour invades immune cells, or
the ability of tumour cells to resist attack by immune cells, and also identify the
tumour invasion properties in the form of the main parameters that should be tar-
geted to mitigate cancer growth in body tissue. Secondly, we seek to study how
virus and immune responses influence the success of oncolytic treatment thus
predicting the success of virotherapy as a cancer treatment in depleting tumour
cells from body tissue. Thirdly, we construct a mathematical model to simulate
chemovirotherapy, a cancer treatment that employs both chemotherapy and on-
colytic virotherapy, use mathematical analysis to predict the efficacy of oncolytic
virotherapy (OV)-drugs combination treatment, and compare the efficacy of using
each treatment, namely, chemotherapy and virotherapy individually. Fourthly,
we also aim to investigate how drug infusion methods determine the outcome
of chemotherapy and virotherapy. Lastly, we develop a model of avascular solid
tumour growth under chemovirotherapy treatment in a two dimensional spatial
domain to study the spatial-temporal effects on chemovirotherapy treatment.
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This study is likely to be of use to medical practitioners in a way that a more
efficacious mode of cancer treatment will be pointed out. Further, this study is
likely to identify the best infusion method for cancer drugs. An investigation into
the tumour invasion characteristics which are most important during invasion
may shade light in the development of effective cancer drugs. Lastly, alternative
cancer treatments, other than chemotherapy, radiotherapy and surgery, will be
suggested in this study.
1.5 Overview of the thesis
This thesis is divided into six chapters. In this chapter we have given background
information and motivation for this research. We briefly discussed the biology
of tumour formation and cancer therapy, reviewed some important mathematical
models on tumour-immune modeling and cancer dynamics, and outlined some
of the important methods which we employ in this thesis.
Chapter 2 describes a model for the analysis of a tumour-immune-immunotherapy
interaction. An estimate of the strength with which a tumour invades immune
cells is made, and we determine the parameters that are most pertinent in tu-
mour invasion dynamics using a traveling wave analysis. Chapter 3 gives a study
of the dynamics of tumour-immune-virus interactions. In Chapter 4 a chemovi-
rotherapy model is developed and analyzed in order to investigate the effects of
chemovirotherapy and the efficacy of chemotherapy and virotherapy treatments,
and also to determine the infusion method that is most efficient in cancer treat-
ment. Chapter 5 is an extension of the work presented in Chapter 4. The chemovi-
rotherapy model is modified to incorporate space thus developing an avascular
solid tumour growth model for chemovirotherapy treatment in a two dimensional
spatial-temporal domain. Chapter 6 contains a general conclusion and discussion
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of the findings in this thesis and suggestions for areas of further study.
Chapter 2
Response of immunotherapy to tumor-
TICLs interactions: A travelling wave
analysis
In this chapter we present a traveling wave analysis of a tumour-immune inter-
action model with immunotherapy. The mathematical model takes into account
local kinetic interactions between cells, the random movement of cells and the
chemotactic response of immune cells once a tumour cell interacts with a tumour
infiltrating cytotoxic lymphocyte. The existence of traveling wave solutions is
proved by establishing a heteroclinic connection between the stable and unstable
manifolds in the apt-phase space. A minimum wave speed of the tumour solitons
is estimated to measure the strength with which a tumour attacks immune cells
or the strength with which immune cells resist being lysed by tumor cells. The
expression of the minimum wave speed highlights the parameters which are most
crucial during tumour invasion, thus indicating the tumour invasion characteris-
tics which need to be targeted in order to mitigate tumour growth. Numerical




Response of Immunotherapy to Tumour-TICLs Interactions:
A Travelling Wave Analysis
Joseph Malinzi, Precious Sibanda, and Hermane Mambili-Mamboundou
School of Mathematics, Statistics, and Computer Science, University of KwaZulu-Natal, Private Bag X01, Scottsville,
Pietermaritzburg 3209, South Africa
Correspondence should be addressed to Joseph Malinzi; josephmalinzi@aims.ac.za
Received 19 March 2014; Revised 10 June 2014; Accepted 19 June 2014; Published 15 July 2014
Academic Editor: Igor Leite Freire
Copyright © 2014 Joseph Malinzi et al.This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
There are several cancers for which effective treatment has not yet been identified. Mathematical modelling can nevertheless point
out to clinicians tumour invasion properties that should be targeted to mitigate these cancers. We present a travelling wave analysis
of a tumour-immune interaction model with immunotherapy. We use the geometric treatment of an apt-phase space to establish
the intersection between stable and unstable manifolds. We calculate the minimum wave speed and numerical simulations are
performed to support the analytical results.
1. Introduction
In travelling wave analysis, the medium moves in the direc-
tion of propagation of the wave. Travelling wave analysis is
important in tumour-immune interaction dynamics since if
travellingwaves exist, thenwemay estimate the potential with
which the tumour cells invade healthy tissue [1]. Tumour-
immune interaction studies have revealed a lot of information
regarding cancer and cancer treatments [2–9] including
cancer dormancy, when tumour cells remain in a quies-
cent state for a long period of time without metastasizing.
Cancer dormancy has been attributed to tumour-immune
interactions, particularly tumour infiltrating cytotoxic lym-
phocytes (TICLs) [2]. Travelling wave analysis could lead
to an understanding of the analytical connection between
model parameters and tumour invasion properties.
Most of the standard cell invasion models are related
to the Fisher-Kolmogorov equation. The Fisher-Kolmogorov
equation [10, 11] is the simplest macroscopic reaction-
diffusion evolution equation for modelling cancer invasion
just as seen in [12]. Many authors, for example, [12–14], have
used the Fisher-Kolmogorov equation in modelling diffusive
tumours and the evolution of cancer on a macroscopic scale.
Several studies have shown that this equation exhibits travel-
ling wave solutions and the minimum wave speed for these
models has been estimated (see [15, 16]). The tumour-im-
mune interaction model presented in this paper employs the
Fisher-Kolmogorov equation to model the random move-
ment of cells. The aim of this paper is to investigate the
existence of travelling wave solutions in a tumour-immune
interaction model with and without immunotherapy and to
estimate the minimum wave speed with which tumour cells
invade healthy tissue. In this way we obtain an estimate of
the strength with which a tumour invades immune cells or
the ability of tumour cells to resist invasion by immune cells
and also identify the tumour invasion properties in the form
of parameters that should be targeted to mitigate cancer in
body tissue. The work presented in this paper complements
the analysis done by Mambili-Mamboundou et al. [17]. They
presented similar model equations, analyzed their equilib-
ria, and found numerical solutions. The main objective in
Mambili-Mamboundou et al.’s work [17] was to ascertain
the cause of cancer dormancy and investigate the effect that
immunotherapy has on the response of TICLs to solid tumour
invasion.
2. The Model
The model considered here was derived by Mambili-
Mamboundou et al. [17]. It subdivides the cell population
Hindawi Publishing Corporation
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Figure 1: Schematic diagram of the local kinetic cell interactions [17].
into local concentrations of primed TICLs 𝐸, tumour cells 𝑇,
interleukin 2 concentration IL2, tumour-immune cell com-
plex 𝐶, a chemokine 𝛼, and resting cells 𝑅. The class IL2
represents a population of cultured immune cells that have
antitumour reactivity with the tumour host. We assume that
IL2 does not necessarily bind with TICLs to form a cell
complex but rather stimulates the TICLs to fight cancer
through lymphocyte activation, growth, and differentiation.
We also assume that IL2 increases the rate of conversion of
resting TICLs to primed TICLs (see [17, 18]). 𝑅 is a class
representing the population of TICLs which have not yet
matured or been activated by antigens. During a tumour
attack on immune cells or any other body tissue infection,
naive or resting TICLs are primed by antigen presenting cells
(APCs) in secondary lymphoid organs such as lymph nodes
and spleen [19]. Figure 1 shows the cells’ local kinetics.
Following the receptor-ligand kinetics theory in [20],
when a tumour cell and an immune cell come into contact,
it may lead to the formation of a tumour-immune complex
at a binding rate 𝑘
1
which later can either lead to tumour cell
death with probability 𝑝 at a rate 𝑘
2
𝑝 or lead to inactivation
of TICLs at a rate 𝑘
2
(1 − 𝑝). In case of the latter, the tumour-





describing the detachment rate of TICLs from tumour cells,
resulting in an irreversible programming of the tumour cells
for lysis. Complex formation reduces both TICLs and tumour
cell densities and increases the complex density by 𝑘
1
𝐸𝑇.









(1 − 𝑝))𝐶, in case the
tumour or immune cell dies.Thebinding of the primedTICLs
to tumour cells leads to the production of a chemokine 𝛼.
The chemokine gradient defines the migration of the TICLs
towards the tumor by a process known as chemotaxis which
is represented by 𝜒∇ ⋅ (𝐸∇𝛼) in the model, with 𝜒 being
the chemotaxis constant. We assume that the rate of supply
of immune cells into the region of tumour localization is
𝜌𝑅, where 𝜌 is the supply rate. We consider the immune
cells proliferation term to be 𝑓𝐶/(𝑔
1
+ 𝑇) and similarly the
chemokine production term to be 𝑓𝐶/(𝑔
3





are constant parameters derived from experimental
results. 𝑓𝐶/(𝑔
1
+ 𝑇) is a function that explains how tumour
cells proliferate as a result of interaction with immune cells.
We consider that all cell densities diffuse at constant rates.
We thus consider the following system of parabolic nonlinear

























































































𝑅 (1 − 𝑏
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, 𝑖 = 1, 2, . . . , 5, are diffusion coefficients of primed
TICLs, tumour, IL2, 𝛼, and resting cell densities, respectively,
and 𝜔 is the rate of stimulation of resting cells into activated
TICLs as a result of injecting a patient with IL2. The capacity
of IL2 to stimulate the production of antibodies is denoted
by 𝑒𝑇 and 𝜃
2
𝐸 ⋅ IL2/(𝑔2 + IL2) is a proliferation term also
considered by Kirschener and Panetta [3]. It models the
stimulation of TICLs by IL2 and is of the Michaelis-Menten









growth terms, respectively, modelling tumour and resting




, 𝑖 = 1, 2, are, respectively, the
growth rates and carrying capacities, 𝑠
2












are, respectively, the resting cells supply rate,
growth rate, and carrying capacity.
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We consider a one-dimensional spatial domain on the
interval [0, 𝑥
0
] and assume that there are two regions in
this interval, one fully occupied by tumour cells and the
other fully occupied by TICLs (both activated and resting).
We propose that the initial interval of tumour localization
is [0, 𝐿], where 𝐿 = 0.2𝑥
0
[2]. In our model, we do not
include the Heaviside function since we consider a resting
cell class. We further assume that these resting cells can
be recruited into the activated cell class. The boundary and
initial conditions therefore are
n ⋅ ∇𝐸 = n ⋅ ∇𝑇 = n ⋅ ∇IL2 = n ⋅ ∇𝑅
= n ⋅ ∇𝐶 = n ⋅ ∇𝛼 = 0 at 𝑥 = 0, 𝑥 = 𝑥
0
,
𝐸 (𝑥, 0) = {
0, 0 ≤ 𝑥 ≤ 𝐿,
𝐸
0
[1 − exp (−1000(𝑥 − 𝐿)2)] , 𝐿 ≤ 𝑥 ≤ 𝑥
0
,
𝑅 (𝑥, 0) = {
0, 0 ≤ 𝑥 ≤ 𝐿,
𝑅
0
[1 − exp (−1000(𝑥 − 𝐿)2)] , 𝐿 ≤ 𝑥 ≤ 𝑥
0
,
IL2 (𝑥, 0) = IL20 , ∀𝑥 ∈ [0, 𝑥0] ,
𝐶 (𝑥, 0) = 𝐶
0
, ∀𝑥 ∈ [0, 𝑥
0
] ,
𝛼 (𝑥, 0) = 0, ∀𝑥 ∈ [0, 𝑥
0
] ,
𝑇 (𝑥, 0) = {
𝑇
0
[1 − exp (−1000(𝑥 − 𝐿)2)] , 0 ≤ 𝑥 ≤ 𝐿,




It has been shown that chemotaxis does not influence the
existence of travelling wave solutions (see, e.g., [1]). We
therefore do the travelling wave analysis without the effect
of chemotaxis. Assuming that the formation of cellular
conjugates occurs on a time scale of a few hours while that
of tumour cells as well as the influx of immune cells into
the spleen occurs on a much slower time scale, probably
tens of hours, and nondimensionalizing the above system























− 𝜓𝐸 − ]𝐸𝑇
+ 𝜔
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(1, 𝑡) = 0,
𝐸 (𝑥, 0) = {
0, 0 ≤ 𝑥 ≤ 𝐿,
[1 − exp (−1000(𝑥 − 𝐿)2)] , 𝐿 ≤ 𝑥 ≤ 1,
𝑅 (𝑥, 0) = {
0, 0 ≤ 𝑥 ≤ 𝐿,
[1 − exp (−1000(𝑥 − 𝐿)2)] , 𝐿 ≤ 𝑥 ≤ 1,
IL2 (𝑥, 0) = IL20 , ∀𝑥 ∈ [0, 1] ,
𝑇 (𝑥, 0) = {
[1 − exp (−1000(𝑥 − 𝐿)2)] , 0 ≤ 𝑥 ≤ 𝐿,
0, 𝐿 ≤ 𝑥 ≤ 1.
(5)
3. Travelling Wave Solutions
In this sectionwe investigate whethermodel (3) exhibits trav-
elling wave solutions or not. We use the geometric treatment
of an apt-phase space to establish the intersection between
stable and unstable manifolds, a method also employed by
Bellomo et al. [1] in investigating travelling wave solutions.
The gist of this method is to establish the presence of a
heteroclinic orbit joining two different equilibrium points in
the phase space. We specify a travelling coordinate 𝑧 = 𝑥−𝑐𝑡,
where 𝑐 the travelling wave speed is greater than zero (𝑐 > 0),
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and let 𝐸(𝑧) = 𝐸(𝑥, 𝑡), ?̃?(𝑧) = 𝑇(𝑥, 𝑡), ĨL2(𝑧) = IL2(𝑥, 𝑡),
and ?̃?(𝑧) = 𝑅(𝑥, 𝑡). For simplicity, we drop the tildes and the

































































































and (6) are transformed into a system of autonomous first
order differential equations as follows:
𝑑𝑋
𝑑𝑧











































































































































, 𝑇, IL21, IL2, 𝑅1, 𝑅)
= 𝑋
0
= (0, 𝐸, 0, 0, 0, IL2, 0, 𝑅) ,
Table 1: Dimensional parameter values for model (1).
Parameter Estimated value Units Source











𝑔 2.02 × 10
7 cells cm−1 [2]
𝑏 2.0 × 10




𝑝 0.9997 Dimensionless [2]
𝑓 0.2988 × 10
8 day−1 cells cm−1 [2]
𝑠 1.36 × 10




























𝜌 6.4 × 10







, 𝑇, IL21, IL2, 𝑅1, 𝑅)
= 𝑋
1
= (0, 𝐸, 0, 𝑇, 0, IL2, 0, 𝑅) ,
(10)
where𝑋0 and𝑋1 correspond to the equilibrium points of the
system (8).
The system (8) can be regarded as an eigenvalue problem
because the wave velocity 𝑐 is unknown. We take 𝑐 = 20, a
value that numerically gives rise to travelling wave solutions.
We chose this value after simulating the system of (3). There
are several other values of 𝑐 that can give rise to travelling
wave solutions. In the next section,we calculate a critical wave
speed below which travelling wave solutions do not exist. We
find a heteroclinic connection between 𝑋0 and 𝑋1, where,












































Here,𝑋0 and𝑋1 are equilibriumpoints of the system (8). Our








𝑋con (𝑧) = 𝑋
1
. (12)
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The existence of such an orbit would imply that travelling
wave solutions do exist [1].











of the vector field 𝑓 at the equilibrium points 𝑋0 and 𝑋1,
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we determine the spectrum of the matrices 𝐷𝑓(𝑋0) and
𝐷𝑓(𝑋
1
). For parameter values in Table 1, 𝐷𝑓(𝑋0) has eight
real eigenvalues (213.22, 27.11, 20, 15.68, −5.35 × 10−9,
−7.11, −15.48, −193.22), four positive and four negative.
The four positive eigenvalues imply the existence of a
4-dimensional unstable manifold 𝑊𝑢(𝑋0). Similarly,
𝐷𝑓(𝑋
1
) has eight eigenvalues (213.2, 27.11, 20, −15.68,
−0.0002, −7.11,−15.48, −193.22), three positive and five
negative, implying the existence of a 5-dimensional stable
manifold𝑊𝑠(𝑋1). From this result, we note that
dim (𝑊𝑢 (𝑋0)) + dim (𝑊𝑠 (𝑋1)) = dimR8 + 1. (16)
Equation (16) suggests that𝑊𝑢(𝑋0) and𝑊𝑠(𝑋1) intersect
transversally along a one-dimensional curve in the eight-
dimensional phase space. This is because the solutions of the
system (8) lie in eight dimensions (8D) but the summation
of the dimension of the stable and unstable manifolds is nine
(9D) just as shown in (16) (see [1, 21]). If this is the case, then
this curve would define a generic heteroclinic connection [1].
This therefore confirms that the system (1) exhibits travelling
wave solutions for certain parameter values.
4. Minimum Wave Speed
In the previous section, we established that (3) exhibits
travelling wave solutions. In this section, we calculate the
minimum wave speed for model (3) with (IL2 ̸= 0) and
without (IL2 = 0) treatment connecting the tumour-free
equilibrium point to the cancer dormant equilibrium point.
In this section we seek the minimum wave speed 𝑐. We apply
the same technique used by Chahrazed [22] and Maidana
and Yang [23] in determining 𝑐. This technique involves
analyzing the phase space by characterizing the equilibrium
points of the autonomous system. The minimum wave speed
corresponds to a change in the eigenvalues of the travelling-
wave differential equations at the equilibrium point ahead of
the wave.
To calculate the minimum wave speed, we impose a
condition that 𝑋0, the tumour-free equilibrium point of
(8), must not oscillate. In other words, the eigenvalues 𝜆
𝑖
corresponding to this equilibrium point must have real
values; that is, 𝜆
𝑖
∈ R. We seek the travelling wave speed both
with and without immunotherapy.
4.1. No Treatment Case. With IL2 = 0, the tumour-free



























































For the equilibrium point 𝑋0 to be biologically meaningful,
𝐸




























































































































































































Thefirst four eigenvalues (19)–(22) are real.Therefore (23)




















𝜙2𝜓 − 𝐶 + 𝐷 = 0, (26)
since we require 𝜆
5,6





















































Substituting parameter values from Table 1 into (27) gives
𝑐 ≥ 4.176. This indicates that the minimum wave speed
𝑐min for the tumour-immune interaction model without
immunotherapy is approximately 4.176.
4.2. Treatment Case. With IL2 ̸= 0, the tumour-free equilib-
rium points of the system (8) are
𝑋
0
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Figure 3: Travelling wave solutions of the system (3) for different travelling wave coordinates with immunotherapy.
The first six eigenvalues (29)–(34) are real provided
that the conditions we have imposed for positivity of
the tumour-free equilibrium point are fulfilled. Equation
(35) or (36) should therefore determine the conditions for
the existence of a minimum wave speed. We set Γ
1
−






= 0 and substituted
parameter values in Table 1. The result gave the value 𝑐 ≥
4.176 as in the case without treatment. This implies that the
minimumwave speed formodel (3) for bothwith andwithout
treatment is the same. In other words, immunotherapy may
possibly not influence the strength with which the tumour
cells attack immune cells because the minimum wave speed
with or without clinical treatment is the same. Fisher’s
equation exhibits travelling wave solutions for 𝑐 ≥ 2 [24].The
minimum wave velocity which we obtained is greater than
two and therefore not a violation of theminimumwave speed
for Fisher’s equation.
5. Numerical Simulations
Using the parameter values in Table 1, we simulate model (3).
These parameter values were obtained from data where the
murine B cell lymphoma was used as an experimental model
of tumour dormancy in mice [25]. The kinetic parameter
values that were obtained in this experiment are shown
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in Table 1. We assumed that 𝑅 and IL2 diffuse at the same







−6) and used the
diffusivity value 10−6 for immune cells by Matzavinos et al.
[2]. We took the travelling wave speed to be 𝑐 = 20 and
implemented the simulations in python using a Runge-
Kutta numerical method. The numerical simulations (see
Figures 2 and 3) indicate that the system of (3) exhibits
travelling wave solutions for certain parameter values. This
supports the analytical results on the existence of travelling
waves in Section 3. Figures 2 and 3, respectively, show the
numerical travelling wave solutions for model (3) without
and with clinical treatment, and for different travelling wave
coordinates. They depict solutions that are periodic and
oscillating around a stable equilibrium state. These solutions
describe heterogeneous cell distributions with a relatively low
tumour cell density. The travelling wave solutions indicate
that tumour cells invade immune cells at a high potential.
The minimum wave speed obtained in the previous section
indicated that themodel exhibits travelling wave solutions for
𝑐 ≥ 4. This is consistent with our numerical simulations for
which we used 𝑐 = 20.
6. Conclusions
Many biological and physical phenomena can be described by
reaction-diffusion equations. However not many nonlinear
reaction-diffusion equations are integrable. It is therefore
imperative to find other quantitative methods for tackling
such nonlinear systems.The objective of this study was to use
a quantitative method to investigate travelling wave solutions
of a tumour-immune interaction model and also identify
the tumour invasion properties in the form of parameters
that should be targeted to mitigate cancer by estimating
the minimum wave speed. We investigated the existence of
travelling wave solutions and estimated the minimum wave
speed of the wave solutions by analyzing the model phase
space. The existence of travelling wave solutions confirmed
that a tumour attacks immune cells at full potential. The
expression from which the minimum wave speed was cal-
culated determined the parameters that need to be targeted
to eradicate cancer in body tissue. We simulated model (3)
and compared the results to analytical results. The numerical
travelling wave solutions depicted periodic cell densities with
a low tumor level, oscillating about a stable equilibrium
state. These solutions depict cancer dormancy which has
been observed in several cancers, for example, osteogenic
sarcomas, basal-cell carcinoma, and breast cancers, and they
also imply that the tumour cells attack the immune cells at
their full potential.













) involved in tumour invasion corresponding to
tumour growth rate, resting TICLs’ growth rate, carrying
capacity of the resting TICLs, resting cells’ supply, diffusion
rate of the tumour cells, and the local kinetic interaction
parameters (tumour cell death and inactivation of TICLs).
The results obtained in this paper are similar to those in
Matzavinos and Chaplain [26]. In their work, they performed
a travelling wave analysis of a model describing the growth
of a tumour in the presence of an immune system response.
Their results showed that indeed a tumor attacks immune
cells at full potential since their model exhibited travelling
wave solutions. In the future, we hope to consider diffusion in
higher dimension due to the fact that body tissue geometry is
highly intricate.
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Chapter 3
Analysis of virotherapy in solid tumor
invasion
In this chapter we study the dynamics of two tumour-immune-virus interaction
models, that is, homogeneous and heterogeneous, with the aim of determining
the efficacy of virotherapy and identifying the most important virus characteris-
tics which are most pertinent during oncolytic virotherapy treatment. A stability
analysis of time invariant solutions for the homogeneous model is presented. The
heterogeneous model is analyzed by determining analytical traveling wave solu-
tions using factorization of differential operators. Both models are numerically
simulated and the solutions are compared to the analytical results.
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a b s t r a c t
Cancer treatment is an inexact science despite traditional cancer therapies. The traditional cancer treatments
have high levels of toxicity and relatively low efficacy. Current research and clinical trials have indicated that
virotherapy, a procedure which uses replication-competent viruses to kill cancer cells, has less toxicity and
a high efficacy. However, the interaction dynamics of the tumor host, the virus, and the immune response is
poorly understood due to its complexity. We present a mathematical analysis of models that study tumor-
immune-virus interactions in the form of differential equations with spatial effects. A stability analysis is
presented and we obtained analytical traveling wave solutions. Numerical simulations were obtained using
fourth order Runge–Kutta and Crank–Nicholson methods. We show that the use of viruses as a cancer
treatment can reduce the tumor cell concentration to a very low cancer dormant steady state or possibly
deplete all tumor cells in body tissue. The traveling waves indicated an exponential increase and decrease in
the cytotoxic-T-lymphocytes (CTLs) density and tumor load in the long term respectively.
© 2015 Elsevier Inc. All rights reserved.
1. Introduction
Cancer is one of the most dreadful and persistent killers. It is a
group of diseases characterized by uncontrolled cell growth. In 2009,
the risk of being diagnosed with cancer before the age of 85 was 1
in 2 for males and 1 in 3 for females [1]. The World Cancer Report, a
publication of the World Health Organization shows that in 2012 the
global incidence of cancer escalated to approximately 14 million new
cases, a figure expected to further rise to an annual 19.3 million by
2025 [2].Cancer treatment is therefore still a major field of research.
Traditional cancer treatments include surgery, chemotherapy, and
radiation therapy. These treatments however all involve a high level of
toxicity and none of them has been found to be a definitive cure to any
cancer [3]. Surgery, which involves the direct removal of the tumor, is
not always a viable option and may lead to fatigue, loss of appetite and
other infections. Radiation therapy involves the use of high ionizing
radiation to kill the tumor cells. It may, depending on which part
of the body is being treated, cause, among other side effects, severe
hair loss. Chemotherapy involves the use of drugs that destroy cancer
cells. Some common side effects of using drugs to treat cancer involve
fatigue, nausea, vomiting, hair loss, mouth sores, and decreased blood
cell count (see Ref. [2]). Modern therapies include immunotherapy
∗ Corresponding author. Tel.: +27 717990712.
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(P. Sibanda), Mambilimamboundou@ukzn.ac.za (H. Mambili-Mamboundou).
and combinations of treatment types. Immunotherapy involves the
use of genetically engineered cytokines which are used to boost the
immune system. This however may not completely cure cancer in
human body tissue (see Ref. [6]). It is therefore imperative to obtain
a treatment with few side effects.
Oncolytic virotherapy uses replication-competent viruses to kill
cancer cells. Specific viruses are turned into therapeutic agents to treat
cancer. The idea of using viruses as a treatment for cancer began in the
1950s, when tissue culture and rodent cancer models were originally
developed [4]. Today, oncolytic treatment involves the use of virus
genomes which are engineered to enhance their anti-tumor speci-
ficity. This began with a study in which thymidine kinase-negative
HSV with attenuated neurovirulence was shown to be active in a
murine glioblastoma model. Since then, the pace of clinical activi-
ties has accelerated considerably, with several trials using oncolytic
viruses belonging to different virus families [5]. To date, clinical trials
have pointed out talimogene laherparepvec as a possible treatment
for melanoma [5]. Clinical trials are ongoing using different viruses as
cancer therapies. There is no recorded toxicity as a result of clinical
use of oncolytic virotherapy to treat cancer [7].
There is however still a dire need to identify the virus charac-
teristics that are most important for therapeutic purposes. Studies
show that cancer cells exposed to viruses have quickly died com-
pared to those that are not. Nevertheless, this cannot be entirely
attributed to viral replication alone but also to cytotoxic-T-cells (CTLs)
[8]. The responses detected as a result of a CTL meeting a tumor cell
are a very important factor in tumor necrosis. Tumor-immune-virus
http://dx.doi.org/10.1016/j.mbs.2015.01.015
0025-5564/© 2015 Elsevier Inc. All rights reserved.
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Fig. 1. Schematic diagram of the local kinetics between a CTL and an infected tumor cell.
interactions are highly complex and poorly understood. Therefore
much effort is needed to understand the tumor-immune-virus dy-
namics. The aim of this study is to use mathematical models to un-
derstand how virus and immune responses influence the outcome of
oncolytic treatment.
Earlier mathematical models that were developed described the
evolution of a tumor under a viral injection [8–11]. A few mod-
els to include an immune response, for example [12,13], have also
been constructed. Our model builds upon the model presented by
Mukhopadhyay and Bhattachrrya [13] with inclusion of local kinetic
interaction terms of tumor cells and CTLs, and a modified functional
immune response to account for the saturation of immune cells in a
tumor localization and the fact that only a portion of a tumor nodule
comes into contact with CTLs (see Refs. [14–16]). Mukhopadhyay and
Bhattachrrya [13] presented a deterministic model to study the dy-
namics of tumor-immune-virus interactions. They showed the im-
portance of different host, viral, and immune system parameters in
controlling the system dynamics. They extended their model to in-
corporate random noise. Our model captures important factors in the
local kinetics and spatial distribution of the cells.
2. The homogeneous model
The model presented here subdivides the cell population into
local densities of CTLs X, uninfected tumor cells Y , and the infected
tumor cells Z, as a result of injecting tissue with an oncolytic virus.
We consider the CTL supply into the tumor cell localization to be
constant. When a single CTL comes into contact with a tumor cell,
following the receptor-ligand kinetics theory in Ref. [18], it leads
to the formation of a tumor–CTL complex which may either lead to
tumor cell death or CTL deactivation. We consider only virus specific
immune response just like in Ref. [13] and thereby not considering
local kinetics between CTLs and uninfected tumor cells (see also Refs.
[5,17]). When the infected tumor cells are destroyed, they release
new infectious virus particles to destroy the remaining tumor. The
virus also stimulates host anti-tumor CTL responses. The local kinetic
interactions between a CTL and an infected tumor are schematically
described in Fig. 1. With the above considerations, the system is




= s − d1X + f Cz
g1 + Z − k1XZ + (k−1 + k2p)Cz,
dY
dt
= a1Y(1 − a2Y)− θZY
g2 + Z ,
dZ
dt
= b1Z(1 − b2Z)+ θZY
g2 + Z − k1XZ + (k−1 + k2(1 − p))Cz, (1)
X(0) = X0, Y(0) = Y0, Z(0) = Z0,




= k1XZ − (k−1 + k2)Cz, (2)
where s is the CTL supply rate into the tumor localization, d1 is the CTL
death rate, f Cz/(g1 + Z) is a response function of Michaelis-menten
form [14] to model the increase in CTL proliferation in the tumor as
a result of a single CTL meeting with an infected tumor cell, where
f and g1 are constant parameters derived from experimental results.
k1 is the binding rate of a CTL to an infected tumor cell to form a
complex Cz, k−1 is a rate at which infected tumor cells get dissociated
from CTLs resulting in an irreversible programming of the tumor cells
for lysis. The probability with which infected tumor cells are killed
through CTL-mediated mechanism once they form a cell complex is
denoted by p and consequently k2p is their rate of death. k2(1 − p) is
the inactivation rate of CTLs. a1Y(1 − a2Y)and b1Z(1 − b2Z)are logis-
tic growth terms respectively modeling uninfected and infected tu-
mor cells where a1 and a
−1
2 , are respectively the intrinsic growth rate
and carrying capacity of the uninfected tumor cells, and b1 and b
−1
2 are
respectively the intrinsic growth rate and carrying capacity of the in-
fected tumor cells. The virus replication into the tumor is modeled by
the function θZY/(g2 + Z) also of Michaelis-menten form [14], where
θ is the virus replication rate. It is important to note that the dynamics
of the lysed cell populations X∗ and Z∗ from the diagram of kinetics in
Fig. 1 do not affect the rates of change of the cell concentrations X,Y ,
and Z. It is therefore sufficient to analyze the behavior given by Eqs. (1).
Biologically, the formation of complexes occurs on a time scale
of a few hours while that of tumor cells and CTLs occurs on a much
slower time scale, of tens of hours [19]. This implies that Ċz ≈ 0. The
system (1) is transformed to
dX
dt
= s − d1X + ρ1XZ
g1 + Z − lXZ,
dY
dt
= a1Y(1 − a2Y)− θZY
g2 + Z ,
dZ
dt
= b1Z(1 − b2Z)+ θZY
g2 + Z − mXZ, (3)
where
l = Kk2(1 − p), ρ1 = f K, m = Kk2p, K = k1
(k−1 + k2).
The parameters in (3) have different units. It is therefore useful
to nondimensionalize this system by setting x = X/X0, y = Y/Y0,
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z = Z/Z0 and t̄ = t/t0. We choose the magnitudes of the concentra-
tions to be X0 = 106 and Y0 = Z0 = 107 since human body tissue can
contain around 105–109 cells (see Ref. [20]). We scale the time rela-
tive to the rate of CTLs’ deactivation, t0 = d−11 . We drop the bar on the
non-dimensionalized time t̄ for notational simplicity and Eqs. (3) are
expressed as
ẋ = σ − x + γ1xz
η1 + z − νxz,
ẏ = α1y(1 − α2y)− θ1zy
η2 + z ,
ż = β1z(1 − β2z)+ θ2zy




, η1 = g1
Z0
, γ1 = ρ
d1
, ν = lZ0
d1
, α1 = a1
d1
,





, β1 = b1
d1
, β2 = b2Z0, θ2 = θY0
Z0d1




3. Asymptotics and stability analysis
We investigate the long term behavior of the solutions to (4) by
calculating the system’s asymptotic solutions. We do this by equating
Eqs. (4) to zero. We investigate the stability of these steady states by




where Ai is the Jacobian matrix of (4) evaluated at the steady state X̄i.
The model (4) has four biologically meaningful steady states;
• Tumor free state: (x, y, z) = (σ , 0, 0). In this steady state both the
infected and uninfected tumor cell concentrations are eliminated
and a complete remission of cancer is possible. The eigenvalues of
(7) evaluated at this state are;
λ1 = α1, λ2 = −1, and λ3 = β1 − μσ .
The tumor free state is unstable, making it virtually impossible to
achieve.
• Infected tumor free state: (x, y, z) = (σ , 1/α2, 0) is a steady state
where the CTLs manage to kill all the infected tumor cells although
the whole tumor is not eliminated since some uninfected tumor
cells remain. The eigenvalues of this state are;
λ1 = −α1, λ2 = −1 and λ3 = α2β1η2 + θ2 − α2η2μσ
α2η2
.
It is locally asymptotically stable only if α2β1η2 + θ2 ≤ α2η2μσ
otherwise it is unstable. The condition for stability does not triv-
ially point out what needs to be clinically done in order to achieve
this state. Nevertheless, it is evident from this condition that
the properties which need to be checked are the intrinsic tumor
growth rates, the virus replication rate, and local kinetic interac-
tion parameters.
• Uninfected tumor free state: (x, y, z) = (x∗, 0, z∗) with
x∗ = A − β1
2Bμ










 = (β1β22η21 + β1η21ν2 − 2 β1β2η1γ1 + β1γ 21
+ 2(β1β2η21 − β1η1γ1)ν)σ − 4((β2η21μν − β2η1γ1μ)σ ).
Here the virus manages to infect all tumor cells. The eigenvalues
of this state are;
λ1 = α1, λ2 = −1, and λ3 = f (A, B,).
This implies that the uninfected tumor free state is unstable ren-
dering it impossible to achieve such a situation.
• Tumor dormancy state: (x, y, z) = (x∗∗, y∗∗, z∗∗), where (x∗∗, y∗∗,
z∗∗) are the roots of the equations
σ − x + γ1xz
η1 + z − νxz = 0,
α1(1 − α2y)− θ1z
η2 + z = 0,
β1(1 − β2z)+ θ2y
η2 + z − μx = 0. (8)
It is a difficult undertaking to calculate the roots to Eqs. (8) because
they are coupled and nonlinear, also involving many terms. How-
ever, we substitute parameter values in Table 1 with θ = 4 and
the steady state solution is (1.84, 0.004, 0.097) which is locally
asymptotically stable since all its eigenvalues (−1.88,−0.256 +
0.04i, −0.256 − 0.04i) have negative real parts. This biologically
signifies that the virus is able to completely reduce the tumor to a
low tumor concentration state which is dormant.
4. Homogeneous model simulations
We study the numerical solutions to the model equations (4)
to substantiate our analytical findings in the previous sections. The
fourth order Runge–Kutta method is used to integrate this system
with the following set of non-dimensional parameter values;
σ = 1.650585, γ1 = 2.3261, η1 = 2.02, ν = 0.0073,
β1 = 2.4272, β2 = 2.0, μ = 0.1455, α1 = 4.3689,
α2 = 1.0, and η2 = 2.02 (9)
with varying values of θ1 and θ2 within the range of θ , the virus
replication rate. These values are obtained by substituting dimen-
sional ones from Table 1 into the expressions in Eqs. (5) and (6).
Our choice of the initial conditions is approximately the infected tu-
mor free state with a fraction of some uninfected tumor cells and
no infected tumor cells to necessitate virotherapy, i.e. x(0) = 1.5,
y(0) = 0.1, and z(0) = 0. The range of θ is as a result of the under-
lying virus characteristics, for example, burst sizes. The local kinetic
Table 1
Dimensional parameter values for the model (1).
Parameter Estimated value Units Source
k1 1.3 × 10−7 day cells−1 cm [20]
k2 7.2 day
−1 [20]
k−1 24 day−1 [20]
p 0.9997 dimensionless [20]
f 0.2988 × 108 day−1 cells cm−1 [20]
θ 0.27 ≤ θ ≤ 4 day−1 cells cm−1 [13]
g1 2.02 × 107 cells cm−1 [20]
g2 10
7 cm3 [13]
s 1.36 × 104 day−1 cells cm−1 [20]





a2 2.0 × 10−9 cells−1 cm [20]
b1 0.1 day
−1 [13]
b2 2.0 × 10−9 cell−1 [13]
φ1 10−6 cells day−1 [20]
φ4 10−4 cells day−1 [20]
χ 1.728 × 106 cm2 day−1 moles −1 [20]
J. Malinzi et al. / Mathematical Biosciences 263 (2015) 102–110 105
Fig. 2. Variation of cell concentrations with time for parameter values as in Eq. (9) and (a) θ = 0.33, (b) θ = 0.8, (c) θ = 2, and (d) θ = 4 respectively. Cell concentrations and time
are nondimensional.
parameter values were obtained from data in which a murine B cell
lymphoma was used as an experiment in modeling tumor dormancy
in mice (see Refs. [20,21]). It is important to note that the kinetic
parameter values are for tumor specific immune response and are
the closest we could find in the literature for virus specific immune
response.
Fig. 2 shows the variation of cell concentrations against non-
dimensionalized time. It shows that as the virus replication rate is
increased, both tumor cell concentrations decrease and converge to
lower concentrations. Initially, there are oscillations in both CTL and
tumor concentrations before they converge to the interior steady
states (a) (x̄, ȳ, z̄) ≈ (9.52, 0.35, 1.16), (b) (x̄, ȳ, z̄) ≈ (3.3, 0.02, 0.57),
(c) (x̄, ȳ, z̄) ≈ (2.07, 0.01, 0.2), and (d) (x̄, ȳ, z̄) ≈ (1.84, 0.004, 0.097).
Fig. 2 clearly shows that it is possible to clear all infected tumor cells
in body tissue for as long as the virus replication rate is high and all
other parameters remaining constant. These numerical results concur
with the stability analysis in the previous section. The stability analy-
sis showed that the tumor free steady state and the uninfected tumor
free states were unstable but the infected tumor free state was feasi-
ble to achieve under certain conditions involving the virus replication
rate, tumor growth rate, and local kinetic interaction terms. It was also
found out, using the same parameter values, that the interior tumor
dormant state is locally asymptotically stable. Numerically, it is also
found that the tumor load (y + z) decreases with increasing values of
θ , the replication rate of the virus. Fig. 3 shows a variation of the tumor
load with time. We notice that the higher the virus replication rate is,
the higher are the chances of curing cancer in body tissue. Further-
more, it depicts cancer dormancy, a phenomenon where all signs and
symptoms of cancer have disappeared, although cancer may still be
in body tissue. This can clearly be seen in Fig. 3 where the tumor load
is reduced to a stable state with a small concentration of tumor cells.
Fig. 4 shows a phase portrait of the tumor load (y + z) against the CTLs
concentration with θ = 0.8. It shows the solution curves converging
to the interior steady state.
5. The heterogeneous model
In this section we incorporate space in model (1). We do this by
considering diffusion in order to capture the random motion of cells
and derivation of nutrients and chemotaxis, the movement of CTLs
toward a specific target following a chemokine gradient. We consider
a one dimensional spatial domain to be the interval [0, r0] and as-
sume that there are two regions in this interval. One fully occupied
by the tumor load and the other fully occupied by CTLs. We denote
the region initially occupied by the tumor load [0, L]. We consider
the same denotation for the cell densities as considered in model 2
and the space variable is denoted by r. Therefore the cell density
solutions are denoted by X(t, r), Y(t, r) and Z(t, r). The chemokine
concentration is denoted by α. We assume constant diffusivity for
all the cell densities. With the above assumptions we have the














+ sH(r)− d1X + ρ1XZ






+ a1Y(1 − a2Y)− θZY






+ b1Z(1 − b2Z)+ θZY







g1 + Z − d2α, (10)
where φ1, φ2, φ3 and φ4 are respectively diffusion constants for
CTLs, uninfected tumor cells, infected tumor cells, and the chemokine
concentration. χ is the chemotaxis constant. The response function
(ρ2XZ/(g1 + Z)) models the multiplication of chemokine concentra-
tion at the tumor location and d2 is the deactivation rate of the
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Fig. 3. Variation of tumor load (y + z) and CTLs with time for (a) θ = 0.33, (b) θ = 0.8, (c) θ = 2, and (d) θ = 4 respectively. The other parameters used are in Eq. (9). Cell
concentrations and time are nondimensional.
Fig. 4. Phase portrait showing the cell concentrations converging to the interior equilibrium point with parameter values as in Eq. (9) and θ = 0.8. The right hand figure is a zoomed
version.
chemokine α. The term sH(r) models the supply of immune cells
in the domain where CTLs lie.
H(r) =
{
0 if r − L ≤ 0,
1 if r − L > 0
represents a heaviside function which divides the domain [0, r0] into
two sections to differentiate tumor and immune cells localization and
also incorporate space competition between the CTLs and tumor cells
(see Ref. [20]). We consider initial and boundary conditions similar to
those considered by Matzavinos et al. [20]. We consider that initially
the uninfected tumor cells occupy a wider domain than the infected
tumor cells with the assumption that virus multiplication will have
just begun and thereby covering a smaller part of the body tissue.
We assume that there is no cell movement at the boundaries of the
domain, (see also Ref. [20]).
The initial and boundary conditions are
X(r, 0) =
{
0, 0 ≤ r ≤ L
X0[1 − exp(−100(r − L)2)], L ≤ r ≤ r0,
Y(r, 0) =
{
Y0[1 − exp(−50(r − L)2)], 0 ≤ r ≤ L
0, L ≤ r ≤ r0,
Z(r, 0) =
{
Z0[1 − exp(−10(r − L)2)], 0 ≤ r ≤ L
0, L ≤ r ≤ r0,
α(x, 0) = 0, ∀ x ∈ [0, r0],
n.∇X = n.∇Y = n.∇Z = n.∇α = 0 at r = 0 and r = r0. (11)
We non-dimensionalize the model (10) by taking X, Y and Z as
fractions of their initial concentrations (x = X/X0, y = Y/Y0, z = Z/Z0)
J. Malinzi et al. / Mathematical Biosciences 263 (2015) 102–110 107
and the chemokine density through some reference concentration,
that is ᾱ = α/α0 where α0 = 10−10 [20] with time τ = t/t0 where
t0 = r0/φ1. We non-dimensionalize the space variable relative to the
space under consideration, that is r̄ = r/r0 where r0 = 1. We assume
L = 0.2 and for convenience, we drop the bar on r and α. The system













+ σH(r)− ψx + γ1xz






+ α1y(1 − α2y)− θ1zy






+ β1z(1 − β2z)+ θ2zy











, ψ = d1t0, η1 = g1
Z0
, γ1 = ρ1t0, ν = lT0t0,
φ̄2 = φ2t0, α1 = a1t0, α2 = a2Y0, η2 = g2
Z0
, θ1 = θ t0,
φ̄3 = φ3t0, β1 = b1t0, β2 = b2Z0 λ = ξα0t0,
θ2 = θY0t0
Z0
, and μ = mX0t0, γ2 = ρ2X0
α0t0
, δ = d2t0.
The initial and boundary conditions become
x(r, 0) =
{
0, 0 ≤ r ≤ 0.2
X0[1 − exp(−100(r − 0.2)2)], 0.2 ≤ x ≤ 1,
y(r, 0) =
{
Y0[1 − exp(−50(r − 0.2)2)], 0 ≤ r ≤ 0.2
0, L ≤ r ≤ 1,
z(r, 0) =
{
Z0[1 − exp(−10(r − 0.2)2)], 0 ≤ r ≤ 0.2
0, 0.2 ≤ r ≤ 1,
α(x, 0) = 0, ∀ x ∈ [0, 1],
n.∇x = n.∇y = n.∇z = n.∇α = 0 at r = 0 and r = 1. (13)
6. Traveling wave solutions
Finding analytical solutions to the system (12) is a difficult under-
taking due to its nonlinearity and the many terms involved. Never-
theless, we can find a certain class of particular analytical solutions
to this system. In this section we use factorization of differential op-
erators, a method developed by Rosu and Corneju [22–24] to deter-
mine traveling wave solutions to the system (12). These solutions
can be helpful in analyzing the tumor-immune-virus dynamics un-
der investigation thus predicting the future cell densities. For the
sake of mathematical simplicity we ignore the heaviside function
and do not consider the effect of chemotaxis. This is a realistic as-
sumption as it has been shown in Ref. [25] that chemotaxis and the
heaviside function do not influence the formation of traveling wave
components.
Factorization of differential operators provides an effective and
efficient way to obtain particular solutions of Lienard type equations.
It has been used in determining exact solutions of some types of
differential equations (see Refs. [26–28]). The equations in system






+ F(U) = 0. (14)
Fig. 5. Initial tumor and CTLs densities for the model (12) showing the tumor load on
one side of the domain and the CTLs on the other.
We use the coordinate transformation ξ = r − cτ and by ap-
plying chain rule, the system (12) is transformed to
d2x
dξ 2
+ G1(x, y, z)dx
dξ
+ F1(x, y, z) = 0,
d2y
dξ 2
+ G2(x, y, z)dx
dξ
+ F2(x, y, z) = 0,
d2z
dξ 2
+ G3(x, y, z)dx
dξ
+ F3(x, y, z) = 0, (15)
where




− ψ + γ1z



















β1(1 − β2z)− γ2y
η2 + z +
θ2y
η2 + z − μx
)]
,
c1 = 1/φ̄2, c2 = 1/φ̄3, and c is the wave propagation speed.
The factorization of (15) gives
[D − ψ11(x, y, z)][D − ψ12(x, y, z)]x = 0,
[D − ψ21(x, y, z)][D − ψ22(x, y, z)]y = 0,
[D − ψ31(x, y, z)][D − ψ32(x, y, z)]z = 0, (16)
where D = d
dξ
. Comparing (15) and (16), it is easy to deduce that
G1(x, y, z) = −
(





G2(x, y, z) = −
(





G3(x, y, z) = −
(






F1(x, y, z) = ψ11ψ12x, F2(x, y, z) = ψ21ψ22y,
F3(x, y, z) = ψ31ψ32z. (18)






− ψ + γ1z
η1 + z − νz
)






α1(1 − α2y)− θ1z
η2 + z
)]






β1(1 − β2z)+ θ2y
η2 + z − μx
)]
, ψ32 = κ3,
where κ1, κ2 and κ3 are arbitrary constants that can be deter-
mined from (18). The system (15) is transformed to eight possible
108 J. Malinzi et al. / Mathematical Biosciences 263 (2015) 102–110
Fig. 6. Traveling wave solutions of the model (12).
Fig. 7. Spatial distribution of nondimensional CTLs and tumor cell densities for the model (12) in the tissue at times corresponding to (a) 300, (b) 400, (c) 700 and (d) 800 days
respectively. The left and right hand scales respectively correspond to CTLs and tumor cell densities.
systems of first order differential equations and we choose to solve the
system (19)
[D − ψ12(x, y, z)]x = 0, [D − ψ22(x, y, z)]y = 0,
[D − ψ32(x, y, z)]z = 0, (19)
which gives
x(ξ) = C exp [κ1ξ ], y(ξ) = C exp [κ2ξ ], z(ξ) = C exp [κ3ξ ], (20)
implying that the analytical traveling wave solutions of the system
(12) are
x(r − cτ) = C exp [κ1(r − cτ)],
y(r − cτ) = C exp [κ2(r − cτ)],



















It is worth noting that the other systems which can be chosen from
(16) are rather not easy to solve because of the many nonlinear terms
involved. We therefore focus on one class of solutions.
Fig. 6 shows plots of the traveling wave solutions which we ob-
tained using factorization of differential operators. They show that in
the long run, the CTL density exponentially grows while both tumor
densities exponentially decrease.
7. Heterogeneous model simulations
Model (12) was simulated using parameter values in Table 1 and
θ = 2. We assumed that CTLs and tumor cells diffuse at the same rate.
We used Crank–Nicholson finite difference schemes to discretize the
model equations and solved the resulting system using LU decom-
position. We implemented this in PYTHON programming language.
Fig. 7(a)–(d) displays the spatial distribution dynamics of CTLs and
the infected and uninfected tumor cells in the tissue at times corre-
sponding to 300, 400, 700 and 800 days respectively. In doing these
simulations, we set two scales on either sides using twinx in PYTHON
software to clearly see the tumor density curves since the scale for the
CTLs is high ([0, 40]) and that for the tumor is low ([0, 1]). We notice
that the CTLs’ density overly keeps increasing with time and the tumor
densities are lowered throughout the tissue going by the areas below
the curves. We estimated these areas using Riemann sums. The areas
under the uninfected tumor curves for 300, 400, 700 and 800 days are
respectively 0.17964, 0.1222, 0.08445 and 0.07261 unit squared. The
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Fig. 8. Nondimensional tumor load and CTLs distribution for the model (12) in the tissue at times corresponding to (a) 300, (b) 400, (c) 700 and (d) 800 days respectively. The left
and right hand scales respectively correspond to CTLs and tumor cell densities.
same is observed for the infected tumor cells, which areas are respec-
tively 0.30472, 0.30472, 0.1840 and 0.15715 unit squared. Comparing
Fig. 7(a)–(d) with (Fig. 5), we notice that the CTLs occupy more of the
domain [0.2, 0.4]. Initially the CTLs lie on [0.2, 1]. As time goes on, the
CTLs occupy much of the left hand domain. This shows the attack of
the CTLs on predator cells. Fig. 8 shows the total tumor load (y + z)
and CTLs spatial distribution. The results are similar to those that we
observe in Fig. 7, that is decrease in tumor load, increase in CTLs, and
a shift of domains depicting an attack of CTLs on the tumor cells. This
can be explained by the response of CTLs to a tumor in body tissue.
8. Conclusions
The advantage of using virotherapy is the fact that it offers less
harmful side effects during and after cancer therapy. Several clini-
cal trials for many viruses are currently ongoing and this treatment
may soon be available for clinical use. The aim of this study was to
examine how virus and immune responses influence the outcome
of oncolytic virotherapy. We constructed two deterministic models
with the second, an extension considering diffusion and chemotaxis.
We determined the homogeneous model’s equilibria and investigated
their stability. We determined traveling wave solutions for the hetero-
geneous model and numerical solutions were compared to analytical
predictions where possible.
The homogeneous model simulations together with the stability
analysis agreed to a fact that virotherapy can reduce the tumor load
in body tissue to a very minimum and cancer dormant cell concentra-
tion level by killing all the infected cells although a very small num-
ber of uninfected tumor cells may remain. Agarwal and Bhadauria
[8] in their tumor-oncolytic virus model analysis argue that the tu-
mor load can be reduced to a lower value provided that the net
growth of uninfected cells is less than the virus transmission rate,
in our case the replication rate. They also conclude that the interior
equilibrium point will always be locally asymptotically stable if the
growth rate of uninfected cells is higher than that of infected cells. The
model parameter values which we used all fulfill the above conditions
and the homogeneous numerical results are similar to Agarwal and
Bhadauria’s. Mukhopadhyay and Bhattacharyya [13] in their analysis
of a deterministic model to ascertain the most important parame-
ters that control tumor-immune-virus dynamics stated that the virus
replication rate has the ability to stabilize or destabilize the system.
Moreover, our homogeneous model simulations clearly indicated that
a high virus replication rate can result into a tumor free body tissue.
We introduced a space variable to incorporate diffusion and chemo-
tactic movement of cells thus developing a spatial model on a one
dimensional domain.
We determined a certain class of analytical solutions to the re-
sulting system of nonlinear hyperbolic partial differential equations.
All the spatial model equations, without chemotaxis, are of Lienard
type and this gave us an advantage to use the method of factorization
of differential operators. The numerical plots of the solutions which
we obtained conformed to the fact that in the long run, CTLs density
exponentially grows while the tumor cell densities decrease. Malinzi
et al. [29] showed that the main tumor invasion properties include
tumor growth rate, tumor cells’ diffusion rate, and local kinetic inter-
action terms. The analytical traveling wave solutions we obtained are
functions of the wave propagation speed, tumor diffusion rates, and
local kinetic interaction terms. Biologically, unchecked exponential
increase or decrease in cell population growth is not realistic in com-
parison to experimental studies (see e.g. Refs. [30–32]). Nevertheless,
these solutions point out a decrease in the tumor cell densities and
an increase in the CTLs. These solutions are similar to those obtained
in the traveling wave analyses done by authors of Refs. [25,33].
The heterogeneous numerical simulations showed the CTLs at-
tacking the tumor. The plots of the total tumor load showed that with
time the CTLs maintained the tumor density at a lower dormant level
while their density kept on increasing in the body tissue.
In reality, the geometry of human body tissue is intricate and
the one dimensional spatial model developed here is not in any way
equivalent to body geometry. Nevertheless the results derived from
110 J. Malinzi et al. / Mathematical Biosciences 263 (2015) 102–110
this model give important insights into tumor-virus-immune interac-
tion dynamics and the model can be extended to a more biologically
realistic geometry, perhaps a spherically symmetric one.
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Chapter 4
Enhancement of chemotherapy using
oncolytic virotherapy: A mathemati-
cal analysis
We have already studied in Chapter 2 the mechanisms of interaction of immune
cells and tumour cells. We have also determined the outcome of oncolytic vi-
rotherapy treatment in Chapter 3. From these studies we noticed that tumour
cells attack the immune system at full potential and that oncolytic virotherapy
may be successful in limiting tumour growth and thereby mitigating cancer devel-
opment but may not completely eradicate tumour cells from body tissue. In this
chapter, we seek to determine the outcome of a combination of treatment types,
in this case chemotherapy and virotherapy. The chapter starts by constructing a
model of chemovirotherapy. The model’s plausibility is shown by proving exis-
tence, uniqueness, positivity and boundedness of the model solutions. As with
the previous homogeneous models, steady state solutions are determined and
their stability is investigated. An efficacy analysis of three drug infusion meth-
ods is done to determine how best to infuse cancer drugs in a human body and
the outcome of each treatment is investigated. Lastly, the models are numerically
simulated and the solutions are compared to analytical results.
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Abstract
We propose a mathematical model of chemovirotherapy, a recent experimental
cancer treatment which combines both chemotherapy and oncolytic virother-
apy. We prove existence, uniqueness, and boundedness of the model solu-
tions. Analytical solutions are determined where possible and stability anal-
ysis presented. Numerical simulations are obtained using the Runge-Kutta
forth order method. We show that chemovirotherapy is capable of reducing
the tumor cell density in body tissue in a relatively short time frame.
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1. Introduction
Tumors possess mechanisms that suppress anti-tumor activity such as lig-
ands that block natural killer cells and cytotoxic tumor infiltrating cell func-
tions [1]. Because of this, successful cancer treatment often requires a combi-
nation of treatment regimens.5
Traditional procedures including chemotherapy, surgery, radiation ther-
apy, and immunotherapy, are not a definite cure for cancer. They are also
highly toxic [2]. Chemotherapy, which is the most commonly used regimen,
Email addresses: josephmalinzi@aims.ac.za (Joseph Malinzi), sibandap@ukzn.ac.za
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involves the use of medical drugs to lyse cancer cells. These chemotherapeutic
drugs circulate in the body and kill rapidly multiplying cells. Because cancer10
cells are fast replicating compared to healthy cells, they are more susceptible
to the action of these drugs [3]. Damage to healthy tissue is unavoidable and
this accounts for the high toxicity of chemotherapy [3].
In the recent past, virotherapy, a less toxic experimental treatment has been
identified as a possible cancer treatment (see [4, 5, 6, 7]). Virotherapy involves15
the use of oncolytic viruses that infect, multiply, and directly lyse cancer cells
with less or no toxicity [6]. Their tumor specific properties allow for viral
binding, entry, and replication [8]. Oncolytic viruses can greatly enhance the
cytotoxic mechanisms of chemotherapeutic drugs [9]. Further, chemothera-
peutic drugs lyse fast multiplying cells and, in general, virus infected tumor20
cells quickly replicate [10].
Nguyen et al. [8] gave an account of the mechanisms through which drugs
can successfully be used in a combination with oncolytic viruses. They how-
ever note that the success of this combination depends on several factors in-
cluding the type of oncolytic virus (OV)-drug combination used, the timing,25
frequency, dosage, and cancer type targeted. This combination of cancer treat-
ment is under clinical trials. There is therefore a need for an investigation into
the treatment characteristics which are most important for its success.
The model we construct combines elements from two different existing
mathematical models. We briefly review these models. Phino et al. [11] de-30
veloped a mathematical model of chemotherapy response to tumor growth
with stabilized vascularization with the aim of investigating the efficacy of
chemotherapy in order to eliminate cancer cells. In their analysis, they showed
the region of parameter space in which cancer cells may be eliminated. They
also showed the outcome of the cell concentrations with varying infusion rates35
of the drug. Other chemotherapy mathematical models include [12, 13, 14].
Ursher [15] also gave a summary of some mathematical models for chemother-
apy. Tian [16] presented a mathematical model that incorporates burst size
for oncolytic virotherapy. His analysis showed that there are two threshold
2
burst size values and below one of them the tumor always grows to its max-40
imum size, while above the other, there exists one or three families of pe-
riodic solutions arising from Hopf bifurcations. His study affirmed that a
tumor can be greatly reduced to low undetectable cell counts when the burst
size is large enough. Other similar virotherapy mathematical models include
[7, 17, 18, 19, 20].45
The major aims of this study are; to construct a mathematical model to sim-
ulate chemovirotherapy, consider three drug infusion methods and compare
their efficacies, use mathematical analysis to predict the outcome of OV-drugs
combination treatment, and to compare the efficacy of using each treatment,
that is to say, chemotherapy and virotherapy individually. We believe that50
these issues have not been addressed in literature before. Further, to the best
of our knowledge, there has not been a mathematical study on the combina-
tion of both chemotherapy and virotherapy, yet theoretical and experimental
studies have shown that chemovirotherapy may be a success in cancer treat-
ment.55
2. Model construction
We consider time dependent cell concentrations of uninfected tumor cells
U(t), infected tumor cells I(t), a free virus population V(t), and a chemother-
apeutic drug C(t) in an avascular tumor localization. The uninfected tumor
grows logistically at an intrinsic rate α per day and the total tumor carrying60
capacity is K cells in a tumor nodule. The infected tumor cells die off at a
rate δ per day. We model the virus multiplication in the tumor by the func-
tion βU(t)V(t), where β is the virus replication rate measured per day per 106
cells or viruses. The response of the drug to the uninfected and infected tumor
is respectively modeled by the functions δ0U(t)C(t) and δ1 I(t)C(t) where δ065
and δ1 are induced lysis rates caused by the chemotherapeutic drug measured
per day per cell. We consider that the virus production is bδI where b is the
virus burst size, measured in number of viruses per day per cell, and δ is the
3
infected tumor cells’ death rate measured per day. We model the chemothera-
peutic drug infusion into the body with a function g(t) and that the drug gets70
depleted from body tissue at a rate λ per day.
We simulate the drug infusion into the body using (a) a constant rate
g(t) = q, (b) an exponential g(t) = q exp (−at) and (c) a sinusoidal func-
tion g(t) = q sin2 (at), where q is the rate of drug infusion. The constant a
determines the exponential drug decay and period for the sinusoidal infu-75
sion. The constant infusion rate may relate to a situation where a patient is
put on an intravenous injection or a protracted venous infusion and the drug
is constantly pumped into the body. This form of drug dissemination is used
on cancer patients who stay in the hospital for over a week. Higher doses
of certain anti-cancer drugs may however lead to hepatic veno-occlusive dis-80
ease, a condition where the liver is obstructed as a result of using high-dose
chemotherapy (see e.g. [21, 22]). The exponential drug infusion simulates a
situation where a cancer patient is given a single bolus and the drug exponen-
tially decays in the body tissue. This form of infusion is not common although
it is now used for some drugs, for example, a single dose of carbonplatin can85
be given to patients with testicular germ cell tumors and breast cancer (see
[23, 24]). The third scenario is possible when a cancer patient makes several
visits to a health facility and is given injections or anti-cancer drugs periodi-
cally. This is a more common form of cancer drug infusion (see e.g. [25, 26]).








İ(t) = βU(t)V(t)− δI(t)− δ1 I(t)C(t),
V̇(t) = bδI(t)− βU(t)V(t)− γV(t),
Ċ(t) = g(t)− λC(t), (1)
subject to initial cell concentrations
U(0) = U0, I(0) = I0, V(0) = V0, and C(0) = C0.
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We re-scale the variables in system (1) by setting t̄ = δt, U = KŪ, I = KĪ,































For simplicity, we drop the bars and equations (1) become
U̇(t) = αU(t) (1−U(t)− I(t))− βU(t)V(t)− δ0U(t)C(t),
İ(t) = βU(t)V(t)− I(t)− δ1 I(t)C(t),
V̇(t) = bI(t)− βU(t)V(t)− γV(t),
Ċ(t) = ξ(t)− ψC(t). (2)
ξ(t) = φ, ξ(t) = φ exp (−at), and φ sin2(at) respectively are the constant, ex-90
ponential and sinusoidal infusion functions. For this model to be biologically
meaningful, its solutions should be positive and bounded because they repre-
sent cell concentrations. In the next section, we show that the solutions to the
equations (1) exist, are positive and bounded, and the domain in which they
lie is positive invariant.95
3. Mathematical analysis
3.1. Existence and uniqueness
Theorem 1. There exists a unique solution to the system of equations (2) in the
region (U, I,V,C) ∈ R4+.
Proof. We use the Picard-Lindelöf theorem (see [27]) as follows.
Consider the closed interval IT = [t0 − T, t0 + T] and the closed ball Bd = {y ∈
Rn| ‖y− x0‖ ≤ d} in Rn where T and d are positive, real numbers. Suppose that
the function
f : IT × Bd → Rn
5
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(t) = f (t, x), x(t0) = x0
has a unique solution on the interval Iδ = [t0− δ, t0 + δ]. It is sufficient to show that
f =

f1 := αU(t) (1−U(t)− I(t))− βU(t)V(t)− δ0U(t)C(t)
f2 := βU(t)V(t)− δI(t)− δ1 I(t)C(t)
f3 := bI(t)− βU(t)V(t)− γV(t)






































exist and are continuous on R4+. The functions (3) and (4) are polynomials and are
therefore continuous on Rn.
3.2. Boundedness and positive invariance
Theorem 2. if U(0) ≥ 0, I(0) ≥ 0, V(0) ≥ 0, and C(0) ≥ 0, then U(t) ≥ 0,
I(t) ≥ 0, V(t) ≥ 0, and C(t) ≥ 0 for all t ≥ 0.105
We use the same idea as in [16] to prove positiveness of the model solu-
tions.
Proof. Assuming that the Theory is not true, then there must be a time t1
such that atleast one of the solutions becomes zero first. We investigate each
6
possible case; if U(t1) = 0 first, then U̇(t1) = 0. However, from the first
equation in system (2), by the uniqueness of the solution, we know thatU(t) =
0 for all t ≥ t1. The second equation then becomes İ(t) = −I(t)− δI(t)C(t)
and its solution is







and so I(t) ≥ 0.
The third equation becomes V̇(t) = bI(t)− γV(t). If you set
V̇(t) = bI(t)−γ = 0 ≥ −γV(t) so V(t) ≥ R exp (−γt) meaning thatV(t) ≥ 0.




φ(s) exp(ψs)ds + C(t1)
)
,
which implies that C(t) ≥ 0 for all t ≥ 0.
If I(t1) = 0 first, then İ(t1) = βU(t1)V(t1) ≥ 0 implying that when t > t1,
I(t) ≥ 0 since U(t),V(t),C(t) ≥ 0 as assumed.110
If V(t1) = 0 first, V̇(t1) = by(t1) ≥ 0, implying that when t ≥ t1, V(t) ≥ 0
since U(t), I(t),C(t) ≥ 0 as assumed.
If C(t1) = 0 first, Ċ(t1) = φ(t1) ≥ 0, so when t ≥ t1, C(t) ≥ 0 since
U(t), I(t),C(t) ≥ 0 as assumed.
If two solutions are zero (eg U(t1) = 0 and I(t1) = 0) simultaneously at115
t = t1, then following the same steps above, it is trivial to check that the other
solutions will be non-negative for t > t1.
If three solutions are zero (eg U(t1) = 0, I(t1) = 0, and V(t1) = 0) si-
multaneously at t = t1, it is trivial to check that the other solution will be
non-negative for t > t1.120
If the four solutions are zero simultaneously at t = t1, from the uniqueness
theorem, U(t) = I(t) = V(t) = C(t) = 0 for t > t1.
Theorem 3. The trajectories evolve in an attracting region D = {(U, I,V,C) ∈
R4+ | U(t) + I(t) ≤ 1, V(t) ≤ b/γ, C(t) ≤ C(φ)}, where C(φ) depends on the
drug infusion function used.125
7
Proof. From equation (1), we know that U + I ≤ K. This implies that U + I ≤
1.
V̇(t) ≤ bI(t)− γV(t), V̇(t) ≤ b− γV(t), V(t) ≤ b
γ













where R is an arbitrary constant of integration. For the constant infusion
function φ, limt→∞ C(t) = φ/ψ. For ξ(t) = φe−at, limt→∞ C(t) = 0, and for
ξ(t) = φ sin2 (at), limt→∞ C(t) = ψ+2a4a2+ψ2 −
φ
ψ .
Theorem 4. The domain D is positive invariant for the model equations (2) and
therefore biologically meaningful for the cell concentrations.130
Proof. The proof directly follows from proofs of Theorems 2 and 3.
3.3. Model solutions
To investigate the efficacy of each treatment and their combination we first
study the dynamics of the system without treatment. Without any form of
treatment, model (2) is reduced to only one equation




(1−U0) exp (−αt) +U0 , limt→∞U(t) = 1,
implying that the tumor exponentially grows to its maximum fractional size.
We next analyze the model (2), firstly without virotherapy, without chemoter-
apy, and then with both treatments incorporated. We firstly obtain, where135
possible analytical and time invariant solutions which predict the long term
dynamics of the model equations (1).
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Without virotherapy (V(t) = 0), the system (2) is transformed to
U̇(t) = αU(t) (1−U(t))− δ0U(t)C(t),
Ċ(t) = ξ(t)− ψC(t), (6)
with U(0) = U0 and C(0) = C0. The second equation in (6) is a first order






where R is a constant of integration. The solution to the first equation in (6)




































Biologically we infer that with a constant drug infusion and without vi-
rotherapy, the tumor is not completely cleared and a certain proportion of
the drug remains in body tissue. The tumor clearance depends on the drug140
induced lysis of the tumor and the drug infusion rate which should be max-
imized, and the tumor growth and drug decay rate which should be mini-
mized.






















































t→∞C(t) = 0, and limt→∞U(t) = U∗,
where U∗ is a fractional tumor cell concentration between 0 and 1. This sug-
gests that with a single dosage infusion of the chemotherapeutic drug with145
exponential decay, and without virotherapy, the tumor cannot be cleared from
body tissue. The drug is also completely depleted from the body.
When ξ(t) = φ sin2(at) is substituted in (6), the resulting differential equa-






ψ2 cos (2 at) e(ψt) + 2 aψe(ψt) sin (2 at)− (4 a2 + ψ2)e(ψt))φ




R = C0 +





t→∞C(t) = C∗ = f (a, φ,ψ) .
This suggests that with time some drug concentration remains in the body tis-
sue. The analytical solution for U(t) is complicated and difficult undertaking
to interpret.150
Theorem 5. The system (6), with constant infusion, has no periodic solutions for
positive U(t) and C(t).
Proof. We use Dulac’s criterion (see [30]) as follows.
Suppose Ẋ = f (x) and f (x) is continuously differentiable on a simply con-
nected domain D ⊂ R. If there exists a real valued function g(x) such that
∇.(g(Ẋ)) = ∇.(g f ) has one sign in D, then there are no closed orbits in D.






































< 0 ∀ U,C ∈ (R+)2.
Theorem 6. The system (6) has atleast two steady states for each of the drug infusion
functions:
155
1. For the constant drug infusion function ξ(t) = φ there are two steady states
of (6); (U = 0,C = φψ ) which is locally asymptotically stable provided that
δ0φ > αψ and (U = 1− δ0φαψ ,C = 0) which is locally asymptotically stable
provided that δ0φ + αψ > 2δ0φψ2 otherwise it is unstable.
160
2. For the exponential drug infusion ξ(t) = φ exp (−at), (6) has two steady
states; (U = 0,C = 0,W = 0) which is unstable and (U = 1,C = 0,W = 0)
which is locally asymptotically stable.
3. For the sinusoidal infusion function, there are four steady states of (6); (U =165








a ) which is locally
asymptotically stable if δ0φ > aαψ and φ < 1.
Proof. 1. It is easy to show that when (6) is equated to zero, one obtains
two steady states. The characteristic polynomial of the Jacobian matrix







λ + δ0φ− αψ,
whose roots λ can only be negative if δ0φ > αψ.
The characteristic polynomial evaluated at (1− δ0φαψ , 0) is
λ2 +
(




λ− 2 δ0φψ2 + δ0φ + αψ,
11
whose roots are negative provided that δ0φ + αψ > 2δ0φψ2.
170
2. By letting W = φ exp (−at), (6) is turned into an autonomous system
U̇(t) = αU(t) (1−U(t))− δ0U(t)C(t),
Ċ(t) = W − ψC(t),
Ẇ(t) = −aW. (12)
The eigenvalues of the Jacobian matrix for (12) evaluated at (0, 0, 0) are
−ψ, α, and 0 and at (1, 0, 0) are −α,−ψ, and −a are all negative.
3. Similarly, by letting W = φ sin2 t, (6) becomes the autonomous system
U̇(t) = αU(t) (1−U(t))− δ0U(t)C(t),
Ċ(t) = W − ψC(t),
Ẇ(t) = [4aW(φ−W)] 12 . (13)
The eigenvalues of the Jacobian matrix for (12) evaluated at (0, 0, 0) are
−ψ, α, and 0 and the eigenvalues evaluated at (1, 0, 0) are ψ,−α, and
0. For the third steady state to exist aαψ ≥ δ0φ and the eigenval-175
ues evaluated at this state are
(
− aαψ−δ0φaψ ,− 4 aφ√4φ(1−φ) ,−ψ
)
, implying
that for it to be locally asymptotically stable, δ0φ > aαψ yet for this to
happen, the steady state will not exist. The eigenvalues evaluated at




− aαψ−δ0φaψ ,− 4 aφ√4φ(1−φ) ,−ψ
)
implying that
this steady state is locally asymptotically stable if δ0φ > aαψ and φ < 1.180
Theorems 5 and 6 show that there are no repetitive patterns in the dynam-
ics of (6) and with a constant drug infusion, the tumor can be eliminated from
body tissue by chemotherapy provided that the combination of the chemother-
apeutic drug induced lysis of the tumor and the drug infusion is greater than
the combination of the intrinsic tumor growth rate and the drug deactivation185
rate. The tumor can also be wiped out with a repetitive type drug infusion
provided that the combination of the tumor induced lysis by the drug and the
dosage is greater than the intrinsic tumor growth rate and drug decay rate.
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With the exponential infusion method, where the chemotherapeutic drug is
only infused in the patient once and it exponentially decays, the tumor is not190
removed from body tissue and may grow to its maximum size.
Without chemotherapy, (2) is reduced to
U̇(t) = αU(t) (1−U(t)− I(t))− βU(t)V(t),
İ(t) = βU(t)V(t)− I(t),
V̇(t) = bI(t)− βU(t)V(t)− γV(t). (14)
The analytical solutions to system (14) are not easy to obtain. We therefore
equate (14) to zero to obtain solutions which are time invariant and investigate
their stability by linearizing (14) about the steady states.
Theorem 7. 1. If β + γ > bβ, the system (14) has two steady states; a tumor free195
cell state (0, 0, 0) which is unstable and an infected tumor free state (1, 0, 0)
which is locally asymptotically stable.
2. If bβ > β + γ, the system (14) has three steady states; the tumor free state




(b− 1)β , I =
αγ (β(b− 1)− γ)
β (β(b− 1)2 + γ(b− 1)) ,V =
α (β(b− 1)− γ)




b > 1 which is locally asymptotically stable if a0, a1, a2 > 0 and a1a2 > a0
where ai are coefficients of the characteristic equation.
Proof. 1. The characteristic equation evaluated at (0, 0, 0) is
λ3 + (γ− α + 1)λ2 + (γ− αγ− α)λ− αγ = 0,
(λ− α)(λ + 1)(λ + γ) = 0,
from which λ1 = α, λ2 = −1 and λ3 = −γ thus rendering it unstable.
The characteristic equation evaluated at (1, 0, 0) is
(λ + α)
(




from which λ1 = −α and λ2 + λ(1+ β + γ) + β + γ− bβ = 0 which are200
all negative since β + γ > bβ.
2. We obtain the same characteristic polynomials as in case 1 and in this
case (1, 0, 0) is unstable since bβ > β + γ, which violates the condition
for the roots to all be negative.
3. The characteristic polynomial evaluated at the tumor dormant state is
λ3 + a2λ2 + a1λ + a0 = 0, where
a2 = (2 Aα + Aβ + Cβ− α + γ + 1) ,
a1 =
(
2 A2αβ− Aαβ + Cαβ− Abβ + 2 Aαγ + Cβγ + 2 Aα + Aβ + Cβ− αγ− α + γ
)
,
a0 = −2 A2αbβ + 2 A2αβ + Aαbβ + Cαβγ− Aαβ + 2 Aαγ + Cβγ− αγ,
and A, B,C are the coordinates of the tumor dormant state. Using Routh-205
Hurwitz stability criterion, this state will only be locally asymptotically
stable if a0, a1, a2 > 0 and a1a2 > a0.
Since the infected tumor free state is undesirable, the reverse of the con-
dition β + γ > bβ is necessary for tumor eradication from body tissue. In
other words bβ > β + γ, that is, the product of the virus replication rate and
their burst size should be greater than the sum of the burst size and virus






It is therefore evident that high virus replication rate β and burst size b lead
to lower tumor cell concentrations. The solutions (15) involve many parame-
ters and thereby giving rise to large expressions in the the conditions for its210
stability. It is therefore a difficult undertaking to infer biological implications
from these conditions. Nevertheless we observe that virotherapy can only suc-
ceed in eliminating cancer from body tissue when the virus deactivation rate
is very small or even zero and the virus replication rate very high.
We next analyze the model with both treatments. For a constant drug215
infusion rate φ, the system (2) has three steady states;
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• Tumor free steady state:(





Here the tumor and viruses are cleared from body tissue by the coupled
treatment and a fraction of the chemotherapeutic drug remains in body
tissue. The eigenvalues of the Jacobian matrix evaluated at this state are
λ1 = − δ0φ− αψψ , λ2 = −
δ1φ + ψ
ψ
, λ3 = −γ, λ4 = −ψ,
implying that this desirable state is locally asymptotically stable if δ0φ >
αψ. From this condition, in order to clear a tumor, the combination of
the rate at which the drug kills the uninfected tumor cells and the drug
infusion must be higher than the tumor growth rate and deactivation of220
the drug from body tissue.
• Infected tumor free state:(
U = 1− δ0φ
αψ





In this state, the whole tumor is not cleared as a fraction of uninfected
tumor cells remain and all the infected ones are cleared by the treat-
ment combination. The eigenvalues evaluated at this state have huge
expressions and the conditions for stability are not trivial. Using well225
estimated parameter values in Table 3.3 the eigenvalues of the Jacobian
matrix evaluated at the infected tumor free state are 0.403, 8.13, and
2.598± 2.418i, implying that the infected tumor free state is unstable.
• Tumor dormant state:(
U =
(δ1φ + ψ)γ
bψ(b− 1)− δ1φβ , I =
Γγ









2 − bβδ0φψ− αβδ1φψ− αδ1γφψ + αbβψ2 + βδ0φψ− αβψ2 − αγψ2
)
(b− 1)β2ψ2 + αβγψ2 − β2δ1φψ
.
It is a difficult undertaking to investigate the stability of this state with-
out substituting parameter values because of the many terms involved.230
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Using the parameter values in Table 3.3, the eigenvalues are −0.031,
−0.025, −1.01, −8.13 implying that this state is stable.
With the consideration of an exponential infusion function ξ(t) = φ exp (−at),
the equations (2) are first turned into an autonomous system of differential
equations by letting W = φ exp (−at). This system has three steady states:235
• a tumor free state where all cell concentrations diminish to zero
(U = 0, I = 0,V = 0,C = 0,W = 0) .
This state is unstable because the eigenvalues −γ, −ψ, −a, −1, and α
are not all negative.
• a state where the tumor grows to its maximum size
(U = 1, I = 0,V = 0,C = 0,W = 0) .
The characteristic polynomial evaluated at this state is (16) and this state
is locally asymptotically stable if β + γ > βγ, otherwise it is unstable.(
U =
γ
(b− 1)β , I =
(αb− α)βγ− αγ2
(b− 1)2β2 + (αb− α)βγ
,V =
(αb− α)β− αγ
(b− 1)β2 + αβγ ,C = 0,W = 0
)
,
b > 1. The eigenvalues evaluated at this steady state are also big expressions
and difficult to analyze analytically and extract conditions for stability. With
the set of parameter values in Table (3.3), the eigenvalues are −0.1 , −8.13,240
1.054, and −0.014± 0.085i implying that this state is stable.
Similarly, with ξ(t) = φ sin2 (at) we change (2) into an autonomous system
of equations by lettingW = φ sin2 (at). The autonomous system has six steady
states:
• Tumor free state where all cell concentrations are wiped out of body
tissue
(U = 0, I = 0,V = 0,C = 0,W = 0) .
The eigenvalues evaluated at this state are −γ, −ψ, −a, −1, and α im-245
plying that it is unstable.
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• A state where the tumor grows to its maximum size
(U = 1, I = 0,V = 0,C = 1,W = 0) .
The condition for stability of this state are same as with the exponential
drug infusion case, that is, the state is locally asymptotically stable if
β + γ > βγ.
• Tumor free state where some concentration of the drug remains(








This state is locally asymptotically stable if δ0φ > αψ and
1
2 < φ < 1
because the eigenvalues evaluated at this state are
δ0φ− αψ
ψ
,− δ1φ + ψ
ψ
,−2 (2 aφ(φ− φ)√
4φ(1− φ) ,−γ,−ψ,
otherwise it is unstable.250
• Infected tumor free state where all infected tumor cells are wiped but a












, aαψ ≥ δ0φ.
• Drug free state where the chemotherapeutic drug is wiped out of body
tissue and proportions of all the other cell concentrations remain(
U =
γ
(b− 1)β , I =
(αb− α)βγ− αγ2
(b− 1)2β2 + (αb− α)βγ ,V =
(αb− α)β− αγ




• Tumor dormant state
U =
(δ1φ + aψ)γ
(ab− a)βψ− βδ1φ , I =
Γ2γ












a2αbβψ2− abβδ0φψ− aαβδ1φψ− aαδ1γφψ− a2αβψ2 − a2αγψ2 + βδ0δ1φ2 + aβδ0φψ
(abβψ + aαγψ− βδ1φ− aβψ)aβψ .
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Table 1: Dimensional parameter values.
K α β δ γ b q λ δ0 δ1
106 0.206 0.001 0.5115 0.001 10 5 4.16 0.005 0.006
[28] [28] [28] [28] [28] [29] [11] [11] estimated estimated
The conditions for stability for the last three states all depend on huge expres-
sions from which it is hard to extract meaningful biological implications. This
analysis however suggests that with both treatments and using a sinusoidal
type infusion, the tumor can be eliminated from body tissue provided that the255
combination of the drug infusion rate and the lysis rate of the tumor is greater
than the combination of the tumor growth rate and rate of drug loss.
4. Numerical simulations
4.1. Parameter values
In this section we use estimated parameter values in Table 3.3 to solve260
model equations (2). These parameter values were obtained from fitted ex-
perimental data for untreated tumors and virotherapy in mice [28]. A 1− 3
mm tumor lump contains about 105 − 109 tumor cells [31]. Therefore we
considered a carrying capacity of 106 cells per unit volume. Several invivo
experimental tumor growth models estimate the intrinsic rate of growth to be265
0.1− 0.3 [32]. We consider the number of viruses produced per day b to be in
the range 10− 1000 (see Ref [29]). We consider the rate of drug infusion q to
be 5 mg/day and the decay rate λ to be 4.17 mg/day, values which conform
to cancer pharmokinetic studies (see eg. Refs[23, 24]). Since infected tumor
cells multiplication is enhanced by the oncolytic virus replication, the tumor270
cells lysis δ1 is considered to be grater that for uninfected tumor cells δ0 (see
Ref [11]).
4.2. Results
We present numerical simulations firstly with only either treatments and
with both treatments implemented. In all our simulations, unless stated oth-275
18
(a)



















































































Figure 1: Solutions of the model without virotherapy (6) showing a variation of fractional
concentrations with time, using (a) a constant , (b) an exponential, and (c) a sinusoidal drug
infusion. The intial cell concentrations are U0 = 0.8, and C0 = 0.2.
erwise, we considered initial concentrations U0 = 1, I0 = 0, V0 = 0.1, and
C0 = 0.1 with a high fractional untreated tumor cell count to necessitate clin-
ical intervention. The equations were integrated using a Runge Kutta fourth
order scheme and implemented in MATLAB. It is worth noting that the scale
for the time and cell concentrations is respectively 1 unit ≈ 2 days and 1 unit280
= 106 number of cells.
Figure 1 shows numerical solutions of the model (6). The figure shows
that a constant and sinusoidal forms of drug infusion are more effective in
19
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Figure 2: Solutions of the model (14) without chemotherapy showing a variation of fractional
cell concentrations with non-dimensional time using low and high values of the virus repli-
cation rate β and burst size b, that is, (a) β = 10−6, b = 10, (b) β = 10−3, b = 10, (c) b = 10,
β = 10−6, and (d) b = 100, β = 10−6.
reducing the tumor concentration as compared to an exponential drug in-
fusion. These numerical solutions agree with the analytical results we earlier285
obtained in the previous sections; that chemotherapy on its own may not clear
all tumor cells in body tissue, the tumor grows to its maximum size and the
drug concentration decays to zero with the use of an exponential infusion. We
noted in Section 3 that total tumor clearance from body tissue can possibly be
achieved if δ0φ > αψ. The parameter values we used however do not conform290
to this condition.
Figure 2 shows the dynamics of the model without chemotherapy. It is
clear from this figure that virotherapy alone could possibly deplete all tumor
cells from body tissue provided that the virus replication rate is high. It is
worth noting that a high virus burst size also leads to similar results, that is to295
say, the higher the virus burst rate, the higher the chances of clearing tumor
20
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Figure 3: Solutions of the model (2) with both treatments showing a variation of fractional
cell concentrations with time using low and high non-dimensionalized values of the virus
burst size, that is, 15, 25 and with diferent drug infusion functions, that is, (a) constant, (b)
exponential and (c) (sinusoidal).
cells from body tissue (also see [16]). Figures 2(a) and (b) show a variation of
the fractional tumor and virus concentrations against time for different values
of the virus replication rate. We notice that with a small virus replication rate
for example β = 10−6, it takes a longer time to clear the tumor cells. Figures300
2(b) and (c) show a variation of the fractional concentrations with two different
burst sizes. From these figures we notice that when b = 10, it takes about
21
10 days to reduce the whole tumor cell concentrations to zero while it takes
only about 5 days with b = 100 implying that a high virus burst size yields
a quick recovery with virotherapy treatment. These numerical intimations305
concur with the analytical results we established in Sub-section 3.3.
Figure 3 displays the dynamics of the model (2) with both treatments.
The numerical results are similar to those of Figure 2, only that with both
treatments it takes a shorter time to bring the tumor cell concentrations to
zero. High values of the virus replication rate and burst size lead to tumor310
clearance in a shorter time period. Both figures 2 and 3 show that an increase
in the virus multiplication rate and burst size increase the infected tumor cells
concentration. For example comparing figures 3(a) and (b) the number of
infected tumor cells were about 0.15× 106 when b = 15 and this increased to
0.35× 106 when b = 25.315
5. Conclusion
The aim of this study was to construct a mathematical model to simulate
the outcome of using both chemotherapy and virotherapy in treating cancer, to
investigate the effect of three different drug infusion methods, and to compare
the efficacy of using chemotherapy and virotherapy individually.320
We constructed a mathematical model in the form of non-linear and non-
autonomous first order ordinary differential equations. We firstly validated
the model’s plausibility by proving existence, positivity and boundedness of
the solutions. We analysed the model with each of the treatments and for each
of the infusion functions. We considered the model with both treatments. We325
found exact solutions where possible and determined the behavior of these
solutions. We investigated the stability of time invariant solutions to deter-
mine the conditions under which a tumor free situation may be achieved. We
simulated the model using a Runge-kutta forth order scheme. The numerical
simulations tallied with the analytical predictions. The model analysis sug-330
gested the following: A tumor can grow to its maximum size in a case where
22
there is no treatment and chemotherapy alone is capable of clearing tumor
cells in body tissue provided that the combination of the drug induced lysis
of the tumor and the drug infusion rate is greater than the combination of
drug decay and tumor growth. That a constant and periodic drug infusions335
are more efficacious than the exponential induction method which biologi-
cally suggests that a repeated-dose regimen in which intravenous injections
are given at regular intervals or putting a patient on an intravenous injection
so that a drug is continuously infused in body tissue is more efficient than
giving a bolus infusion. The model analysis also suggested that successful340
virotherapy is highly dependent on a large virus burst size and a higher virus
replication rate and that with the use of both chemotherapy and virother-
apy, a tumor may in less than a month be cleared from body tissue. Lastly,
successful chemovirotherapy depends on the virus burst size and replication
rate, chemotherapeutic drug lysis, infusion and decay rates, and the method345
of drug infusion.
Biologically, the reduction of a tumor to undetectable levels in less than
a week is unrealistic in comparison to existing clinical and research studies
(see e.g. [33]). The duration of cancer treatment depends on several factors
including the type of cancer being treated and the patient cells’ characteristics.350
This makes it hard to predict the time period to clear a tumor in body tissue.
Moreover, a tumor may be reduced to insignificant levels but later reappear
[34]. Nevertheless, our study shows that chemovirotherapy is highly likely to
bring the tumor to undetectable levels in a short time period.
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Spatiotemporal dynamics of chemovi-
rotherapy
This chapter is an extension of the study in Chapter 4. The model developed to
simulate chemovirotherapy is extended to incorporate diffusion and thereby cap-
turing the spatial cell distributions. Steady state solutions for the homogeneous
part of the model are obtained and their stability is investigated. Model solutions
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Abstract Theoretical and experimental studies have indicated that the combination
of chemotherapeutic drugs and oncolytic viruses to eradicate tumours from body tis-
sue is less toxic than traditional cancer treatments. For this reason chemovirotherapy
could be an efficacious cancer treatment. Nevertheless, thetherapy interaction dy-
namics and drug-virus combination factors necessary for successful treatment are
poorly understood. A spatiotemporal mathematical model, in the form of parabolic
nonlinear partial differential equations, is constructedto simulate avascular solid tu-
mour growth, under chemovirotherapy, in a two dimensional sp tial domain. The
homogeneous model is analyzed by investigating the stability of its time invariant
solutions. The heterogeneous model, in one dimension, is solved using factorization
of differential operators to obtain analytical traveling wave solutions. Finally, numer-
ical solutions are determined using pdepe, a finite element based method in Matlab,
and a multi-domain monomial collocation method. The numerical results show both
the chemotherapeutic drug and the virus attacking the tumour fr m outside the body
tissue, and the tumour densities getting depleted from bodytissue with time. The
traveling wave solutions point out the tumour growth rate, diffusivities, and virus and
drug decay rates as the most critical parameters in chemovirotherapy treatment.
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1 Introduction
Total elimination of a tumour from body tissue using virotherapy requires high dozes
of oncolytic viruses which may be lethal to normal tissue cells (Toyoizumi et al,
1999). Using chemotherapeutic agents can counter balance theseviral induced toxins
thus eliminating the tumour without harm to body tissue (Aghi et al, 2006; Alonso
et al, 2007; Siurala et al, 2015).
Chemovirotherapy is a cancer treatment under clinical trials. It combines both
chemotherapy and virotherapy treatments. The essence of using this combination is
that oncolytic viruses directly lyse tumour cells or deliver g nes that make them more
susceptible to chemotherapeutic drugs. Some oncolytic viruses used in chemothera-
peutic trials have reached phase three out of five of clinicaltri ls and may therefore
soon be released to the general public for use, for example, the reovirus for treating
head and neck cancer (Binz et al, 2015). Pre-clinical and experimental studies, for ex-
ample (Binz et al 2015; Ungerechts et al 2007; Bossow et al 2011; Zaoui et al 2012;
Tusell Wennier et al 2012; Shafren et al 2004; Kumar et al 2008; Liu et al 2007),
have indicated that this type of treatment is capable of eliminating tumour cells with
no harm extended to body tissue. Nevertheless, there is a dire need for further studies
to describe and characterize the tumour-virus-chemotherapeutic drug interactions.
Mathematical modeling can be an avenue for describing the chemovirotherapy
dynamics and determining the drug and virus combination factors, in form of param-
eters, which are most vital in tumour clearance. The outcomef chemovirotherapy
treatment can also be predicted using mathematical modeling. We construct a spa-
tiotemporal model to consider movement and spatial distribution of cells with the
aim of investigating the outcome of chemovirotherapy treatment and determining the
drug and virus combination factors, in the form of parameters, which are most critical
during chemovirotherapy treatment.
2 Model construction
We develop a model that describes an avascular solid tumour gr wth under chemother-
apy and virotherapy treatments in a two dimensional spatialdomain. We consider
tissue composition with the following variables: densitieof uninfected tumour cells
U(r,t), infected tumour cellsI(r, t), a virusV(r,t), and a chemotherapeutic agent
C(r,t), wherer ∈ [0,L] is the radius of the tumour at a timet ∈ [0,∞). We consider
an avascular tumour, with a necrotic core containing dead cells with a radiusL0, in a
radially geometric setting with a fixed radiusL. We assume that the tumour has grown
to its maximum size and it is just prior to angiogenesis, an assumption to necessitate
3
clinical intervention. We model the movement of cells usingthe Kolmogorov equa-
tion (seeMa and Fuchssteiner 1996), a linear diffusion model used for simulating cell
movement.
Fig. 1 Representation of the tumour geometry. The tumour radius is L, a size beyond which it mes-
tasizes, with a necrotic core of radiusL0
Figure1 is a geometrical representation of the tumour with radiusL and a necrotic
core of sizeL0.
Tumour density,U(r,t) andI(r,t)
The tumour is considered to grow logistically at an intrinsic ratea per day and its car-
rying capacityK is taken to be 106 cells. The infected tumour density increases as the
oncolytic viruses multiply in the uninfected tumour cells and burst. We consider the
virus replication into the tumour to be of Michaelis-Mentenform (see (Wagner, 1973;
Malinzi et al, 2015)). We also assume that the drug kills the tumour cells in a concen-
tration dependent manner (Fornari et al, 1994), that is, the drug cytoxicity increases
with increasing drug concentration, asymptotically approaching its maximum. The








































− δI , (2)
whereD1 andD2 are diffusion coefficients of the uninfected and infected tumo r
densities respectively.β is the virus multiplication rate measured per day per cells,
δ0UC/(Kc +C) and δ1IC/(Kc +C) are receptively the chemotherapeutic drug re-
sponses to the uninfected and infected tumour cells whereδ0 and δ1 are respec-
tively the lysis induced rates measured per day.ku andKc are respectively Michaelis-




We consider a virus productionbδI whereb is the virus burst size measured per day
andδ is the infected tumour cell death rate measured per day. The virus gets deacti-
vated in body tissue at a rateγ per day. We consider that the virus is locally delivered

















whereD3 is the virus diffusion constant.
Drug density,C(r, t)
We consider that the chemotherapeutic drug is administeredas a single bolus and
its concentration in the blood stream exponentially decaysjust as in (Stamper et al,
2010). We model penetration of the drug into the tumour using reaction diffusion.














whereD3 is the chemotherapeutic drug diffusion coefficient,Cb(t) := σe(−kct) is the
prescribed drug plasma level in the blood stream, andλ is the natural drug density
decay measured per day. The constantσ is the initial drug concentration andk relates
to the chemotherapy drug half lifeT1/2, which is roughly one day (Ribba et al, 2005),





3 Initial and boundary conditions
We assume that the uninfected tumour density in the necroticc re is zero and that it
increases towards the outside of the tumour, that is, in the quiescent and proliferating
zones (see for exampleMalinzi et al 2015). We assume that the initial drug and virus
densities lie on the sheath of the tumour in small concentrations. We assume that
there is no flux at the boundary= 0 for all cell densities because of the geometry
considered. At the boundary= L, we assume no flux conditions for the infected and
uninfected tumour cells, and the virus density. We considerthat the chemotherapeutic
drug diffuses into the tumour through the outside tumour boundary r = L whose
permeability is denotedρ and that the virus density at the boundary is determined by
the tumour-virus interactions. With these assumptions we close off the system (1-4)
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with the following initial and boundary conditions:
U(r,0) =
{





, L0 ≤ r ≤ L,
I(r,0) = 0, r ∈ [0,L]
V(r,0) =
{


















































whereL0 is the radius of the necrotic core.
Model re-scaling
The system (1-4) is re-scaled by settinḡU = U/K, Ī = I/K, V̄ = V/V0 andC̄ = C/C0
with t̄ = t/t0 and ¯r = r/L whereL = 1 mm andt0 = r0/D1. The parameters become
φi = Dit0, i = 1,2,3,4, α = at0, β̄ =
βV0t0
U0







, δ̄1 = δ1C0t0, b̄ =
bK
V0
, γ̄ = γt0, σ̄ =
σt0
C0




Dropping the bars for notationality simplicity and taking the necrotic core to be
of radius 0.2mm (see RefGarcía-García et al 2007) gives a re-scaled model defined

































































with the initial and boundary conditions (11) & (12).
U(r,0) =
{
0, 0≤ r ≤ 0.2
1−e(−100r−L0)2, 0.2≤ r ≤ 1,
I(r,0) = 0, r ∈ [0,1],
V(r,0) =
{






















































Firstly, we present results for the model analysis without spatial dynamics, that is,
model predictions of the cell densities at different time periods without the consider-
ation of space. Without spatial effects the model equations(7-10) become










− δI , (14)
V̇(t) = bI− βUV
Ku +U
− γV, (15)
Ċ(t) = Cb(t)−µC. (16)
The Equations (13-15) are highly non-linear and difficult to solve. Equation (16)
is a first order linear differential equation and can be solved using a suitable integrat-






e−(kct), R= C0 +
σ
kc−µ, limt→∞C(t) = 0. (17)
Equation (17) shows that with time the drug concentration is depleted from body
tissue. By equating (13-16) to zero we obtain the following steady states to which
the cell concentrations may converge after a long time period; the tumour can be
eradicated from body tissue, namely,U = 0, I = 0,V = 0,C = 0 or it can grow to its
7






(δγku−bβ + βδ+ δγ)αγku
(αγku +bβ−βδ− δγ)(βδ+ δγ−bβ),
V =
(δγku−bβ + βδ+ δγ)α(b− δ)ku
(αγku +bβ−βδ− δγ)(βδ− δγ−bβ).

(18)
The characteristic polynomial of the Jacobian matrix evaluated at the tumour free
steady state has both positive and negative real roots, thatis,−γ,−µ,−k,α,−1. This
shows that the tumour free state is unstable and therefore unattai able. The other
states are stable or unstable depending on the parameter valu s, mostlyKu,Kc, andβ.
This implies that without the consideration of space, the homogeneous model predicts
that, the tumour may either co-exist with the virus or it may grow to its maximum
size depending on several conditions as defined by the parameters in (18). Equation
(18) shows that with time, except for the chemotherapeutic drug, all tumour densities
co-exist in body tissue. It also shows that high values of thevirus burst sizeb and the
virus replicationβ lead to lower tumor densities.
3.1 Traveling wave solutions
In this section we employ the factorization of differentialoperators method (Mal-
inzi et al, 2015; Rosu and Cornejo-Pérez, 2005; Cornejo-Pérez, 2008) to determine
traveling wave solutions to the system (7-10) in one dimension. This method leads
to particular solutions of Lienard type equations (Rosu and Cornejo-Pérez, 2005;
Cornejo-Pérez, 2008). Using the transformationζ = r − ct, wherec is the propaga-








































































whereci = 1/φ̄i , i = 1,2,3,4.
The factorization of Equations (19-22) gives sixteen possible systems of first or-
der differential equations
[D−ψ11(U, I ,V,C)][D−ψ12(U, I ,V,C)]U = 0, (23)
[D−ψ21(U, I ,V,C)][D−ψ22(U, I ,V,C)]I = 0, (24)
[D−ψ31(U, I ,V,C)][D−ψ32(U, I ,V,C)]V = 0, (25)
[D−ψ41(U, I ,V,C)[D−ψ44(U, I ,V,C)]C = 0, (26)


































F1 = ψ11ψ12U, F2 = ψ21ψ22I , F3 = ψ31ψ32I , F4 = ψ41ψ42C. (31)









































, ψ42 = γ4,
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whereγi , i = 1,2,3,4 are constants that can be determined from the equation
(27-30). We choose to solve the differential equations
[D−ψ12]U = 0, [D−ψ22]I = 0, [D−ψ32]V = 0 [D−ψ42]C = 0, (32)
which gives
U(ζ) = κ1e[γ1ζ], I(ζ) = κ1e[γ2ζ],V(ζ) = κ1e[γ3ζ],C(ζ) = κ1e[γ4ζ] (33)
U(ζ) = κ1e(γ1ζ) = κ1e(γ1(r−ct)), (34)
I(ζ) = κ2e(γ2ζ) = κ1e(γ2(r−ct)), (35)
V(ζ) = κ3e(γ3ζ) = κ1e(γ3(r−ct)), (36)
C(ζ) = κ4e(γ4ζ) = κ1e(γ4(r−ct)), (37)
From equations (27-30) the constants are determined to be
































Equations (34-37) are cell traveling wave solutions which we determined fromthe
choice of differential equation which we made. These solutins are all of exponential
form and they all suggest thatγi should be less than zero, that is,γi < 0 for all the
cell densitiesU, I ,V,C to decay to zero asζ, the traveling wave co-ordinate tends to
infinity. It is worth noting that the other sets of differential equations in (23-26) arising
from different choices are rather difficult to solve due to their non-linearities and
the many terms involved. The equations (38-41) highlight the parameters which are
critical in chemovirotherapy treatment. These parametersinclude the cell diffusion
constants, tumour growth rate, infected tumour death rate,and the virus and drug
decay rates.
3.2 Heterogenous Model simulations
In this section we present results from numerical simulations f the models (7-10)
which describes the spatiotemporal dynamics of an avascular tumour under chemovi-
rotherapy treatment. It is not an easy undertaking to find analytic l solutions to the
10
Fig. 2 Fractional tumour cell densities att = 0 with the necrotic core lying in the region 0≤ r ≤ 0.2.
equations (7-10) because it is highly coupled and involves many terms. In this section
we use a multidomain monomial based collocation method (Motsa, 2015) and pdepe
(Skeel and Berzins, 1990), a finite element based method in Matlab, to determine
numerical solutions to the system (7-10).
The parameter values we used were obtained from fitted experimental data for
untreated tumors and virotherapy in mice (Bajzer et al, 2008). We considered the car-
rying capacity of the tumour to be 106 cells per unit volume because a tumour nodule
contains about 105 to 109 tumour cells (Spratt et al, 1996). The tumour growth rate
was taken to be 0.26 per day because several experimental tumour growth models
estimate it to be in the range 0.1 to 0.3 (Benzekry et al, 2014). The number of viruses
produced in a day is considered to be in the range 10 to 1000 (see RefBrock 1990).
The rate of drug infusion into body tissue is taken to be 20 mg/day since most can-
cers require high dozes of treatment and the drug decay rate is estimated to be 4.17
mg/day, values which concur with cancer pharmokinetic studies (see for example
RefsBosl and Patil 2011; Oliver et al 2011). Since infected tumor cells multiplica-
tion is enhanced by the oncolytic virus replication, the tumor cells lysis is considered
to be grater that for uninfected tumor cells.
Figure2 shows the initial tumour distributions. It shows that the tumour density is
zero in the necrotic core and increases towards the sheath ofthe tumour. The infected
tumor density is zero throughout the tissue. We firstly simulate the equation (7) which
models tumour growth without any form of treatment (C = V = I = 0) to investigate
the efficacy of each treatment and their combination.
Figure3 shows the distribution of tumour cells in the tissue withoutany form
of treatment. The tumour density is zero at the center and it increases towards the
outside of the tissue. The figure shows that with time the tumour density increases.
11






























Fig. 3 Spatial distribution of fractional untreated tumour density in the tissue at times correspond-
ing to (a) 200, (b) 400 (c)600, and d) 1000 days respectively.
Fig. 4 Fractional drug density distributions for different time periods.
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This can be seen from Figure3 (a)-(d), where even after 1000 days the fractional
tumour density rose to 4× 106 cells per unit volume from 1.2×106 cells per unit
volume. Figure4 shows the fractional distribution of the chemotherapeuticdrug in
body tissue. It shows that the drug density is highest insidethe tissue. It also shows
that the density is reduced with time. Initially the fractional drug density is maximum
outside the tumour and with time it circulates in the tumour and redistributes to have
a higher density inside the tissue, that it, maximum concentration is near the core than
outside wherer ≥ 0.2.
We have determined numerical solutions of a tumour without any form of treat-
ment and a chemotherapeutic drug in body tissue. We next simulate chemotherapy
and virotherapy treatments to determine how the drug and virus treatment affects the
tumour density and spatiotemporal distribution. Later we combine both treatments to
simulate chmovirotherapy. Figure5 shows numerical solutions of Equation (7) which
simulates the tumour with chemotherapy treatment. The tumour density in the tissue
is reduced with time. Comparing the results in Figures3 to 5, we note that the tumour
density was reduced to 0.04×106 - 0.065×106 cells per unit volume in 2000 days
whereas with the case with no treatment, even after 1000 daysthe fractional tumour
density only reduced to 0.193×106 - 0.196×106 cells per unit volume.
Figure6 is a numerical representation of tumour treatment with virotherapy sev-
eral days after administration of the treatment. We note that with time the virus re-
duces the uninfected tumour density and the infected tumor density first increases
and then decreases, going by the areas below the curves. These areas were estimated
using Riemann sums. Initially we assume that there are no infected tumour cells in
the tissue and that the tumour has grown to its maximum size. Aft r a period of 10
days, Figure6(a) shows that the uninfected tumour density begins to reducand the
infected tumour density begins to increase from the right boundary, that is, from out-
side the tissue. After 100 days, and comparing to Figure6(a) to6(d), the uninfected
tumour density was reduced from 0.792 to 0.098 square units.The infected tumour
density solutions are inform of a traveling wave front propagating from the right to
the left.
Figure7displays the spatiotemporal dynamics of the tumour with botchemother-
apy and virotherapy treatments combined. The figure shows that with time the tumour
density is reduced from both ends of the tissue, that is, frominside and outside the
tissue. We notice that with time the infected tumour density, just like with the vi-
rotherapy treatment, first increases and then decreases. Comparing Figures6 and7
we discover that the tumour is attacked by both the virus and the drug from outside
the tissue. The areas under the uninfected tumour curves forthe 10, 25, 50, and 100
days are respectively 0.41, 0.35, 0.12, and 0.09 square units.
13






































Fig. 5 Spatial distribution of fractional tumour density in the tissue after incorporating chemother-
apy at times corresponding to (a) 10, (b) 100 (c)1000, and d) 2000 days respectively.
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Fig. 6 Spatial distribution of fractional uninfected and infected tumour densities with virotherapy
treatment for times corresponding to (a) 10, (b) 25 (c)50, and d) 100 days respectively.
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Fig. 7 Spatial distribution of fractional uninfected and infected tumour densities with both treat-
ments for times corresponding to (a) 10, (b) 25 (c) 50, and (d)100 days respectively.
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4 Discussion
The main purpose of this study was to propose a spatiotemporal m del to simulate
avascular tumour growth under chemovirotherapy treatmentwith the aim of deter-
mining the outcome of combining drugs with oncolytic viruses in order to eliminate
tumours from body tissue and also to determine the parameters which are most criti-
cal during chemovirotherapy treatment. We constructed a mathematical model of an
avascular tumour which has grown to its maximum size and under ch movirother-
apy treatment. The resulting mathematical model equationswere solved using pdepe
and a multi-domain monomial based collocation method. Analytical traveling wave
solutions of the heterogeneous model, in one dimension, were also determined. The
traveling wave solutions depicted that the most critical parameters during chemovi-
rotherapy treatment are ; cell diffusion constants, tumourgrowth rate, infected tumour
death rate, and the virus and drug decay rates. The numericalsimu ations revealed
that chemotherapy or virotherapy alone may not be capable ofd pleting tumour cells
in body tissue but a combination of the two is capable of eradicating tumour cells and
in a relatively short time period. The numerical solutions also showed the virus and
the drug lysing the tumour from outside the tissue.
Tumour cell propagation and progression may take several months or years. Nev-
ertheless, one may not live for many years with cancer, and without treatment unless
if it is in a dormant situation. The 1000 days for which we simulated a tumour with-
out any form of treatment may not be plaussible but we can infer that even after
several years, without any clinical intervention, cancer may result to death and that
chemovirotherapy treatment is capable of attenuating it.
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Chapter 6
Conclusion
This thesis was primarily concerned with modeling the role of the immune sys-
tem response to tumour invasion and investigating the outcome of some new
forms of cancer treatment. We used mathematical modeling techniques, which
are described herein. The mathematical models which we constructed are in the
form of ODEs and PDEs which allow for future predictions and investigation of
spatial density distributions.
In Chapter 2, we investigated the presence of traveling wave solutions in a tumour-
immune interaction model with immuotherapy, and calculated the minimum
wave speed. The purpose of this chapter was to measure the strength with which
a tumour attacks immune cells and to determine the most important factors, in
the form of parameters, which should be targeted to mitigate tumour growth.
The presence of traveling wave solutions was investigated using the method em-
ployed by Bellomo et al. [76]. We established the presence of a heteroclinic orbit
joining two different equilibrium points in the phase space in which the solutions
were defined. The model was shown to exhibit traveling wave solutions and this
confirmed that a tumour attacks immune cells at full potential. The numerical
solitons depicted periodic cell densities with a low tumour level, oscillating about
a stable equilibrium state. These solutions depict cancer dormancy which has
previously been observed in several cancers, for example ostoegenic sarcomas,
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basel-cell carcinomas, and breast cancers. The parameters which we noted as the
pivotal ones during tumour invasion are; tumour growth rate, resting immune
cell growth rate, carrying capacity of the resting TICLs, resting cell supply, diffu-
sion rate of the tumour cells, and the local kinetic interaction parameters, namely,
tumour cell death and inactivation of TICLs.
In Chapter 3, two deterministic models to simulate virotherapy were developed
and analyzed. We noted earlier, in Chapter 1, that there is a need to investigate
the outcome of the new forms of cancer therapy and also determine which condi-
tions are necessary in order to mitigate tumour growth. The stability analysis of
the homogeneous model, together with the numerical solutions, confirmed that
virotherapy can reduce the tumour load in body tissue to a very minimum and
cancer dormant cell concentration level, by killing all the infected cells. A small
number of uninfected tumour cells may remain, depending on the virus charac-
teristics, mostly the virus replication rate. We showed that oncolytic virotherapy
as a cancer therapy is most effective if the virus used in the treatment rapidly
replicates, that is, if the virus replication rate is very high. The stability analysis
of the homogeneous model’s steady states revealed the existence of an unstable
tumour free state, implying that achieving a cancer free state in body tissue could
be practically impossible. Nevertheless, the same analysis showed the existence
of a tumour dormant state where the tumour in very small concentrations can
co-exist with immune cells. We determined a certain class of solutions to the het-
erogeneous model using the factorization of differential operators. All the spatial
model equations, without chemotaxis, are of Lienard type. These traveling wave
solutions showed that in the long run the immune cell density grows exponen-
tially while the tumour cell densities decay exponentially. These solutions are all
functions of the wave propagation speed, tumour diffusion rates, and local ki-
netic interaction terms; parameters which were determined in Chapter 2 as being
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central to the process of tumour invasion. The heterogeneous numerical simula-
tions showed an attack on the tumour by the immune cells. The plots of the total
tumour load showed that with time the immune cells maintained the tumour den-
sity at very low dormant levels while their spatial distribution kept on increasing
in the body tissue.
In Chapter 4, we constructed a simple model to simulate chemovirotherapy treat-
ment with the aim of investigating the effect of three different drug infusion meth-
ods, and individually comparing the efficacy of chemotherapy and virotherapy.
We showed the plausibility of the model by proving existence, positivity and
boundedness of the solutions. The model was analysed by determining analytic
solutions where possible, and stability analysis of its steady states. The model
was also numerically simulated and the solutions matched with the analytical
results. The model analysis showed that a tumour can grow to its maximum
size in case there is no treatment. Chemotherapy alone is capable of clearing
tumour cells in body tissue provided that the combination of the drug induced
lysis of the tumour and the drug infusion rate is greater than the combination
of drug decay and tumour growth. We noted that constant and periodic drug
infusions are more efficacious than the exponential induction method. This bio-
logically suggests that a repeated-dose regimen in which intravenous injections
are given at regular intervals, or putting a patient on an intravenous injection so
that a drug is continuously infused in body tissue, is more efficient than giving
a bolus infusion. We discovered that virotherapy as a treatment form is highly
effective provided that a large virus burst size is ensured for the viruses used
during treatment. The analysis of the combined drug-virotherapy treatment re-
vealed that chemovirotherapy may be a definite cancer treatment provided that
the drug used is infused at a high rate, decays at a very low rate, and has a high
rate of lysis of tumour cells. Further, the virus used should have a large burst size
probably each with the capacity to produce about one hundred viruses per day.
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This specific result tallies with the results obtained in Chapter 2 where we noted
that successful virotherapy is dependent on the virus replication rate which, in
this case, is a combination of the burst size and infected tumour cell death rate.
Ben-Jacob et al. [77] noted that the three major challenges in cancer modeling
studies are concerned with understanding cancer dormancy and relapse, mul-
tidrug therapy and immune resistance, and metastatic colonization. This thesis
sought to address two of these issues, namely, cancer dormancy and cancer ther-
apy combinations. Nonetheless, it is impractical to incorporate all the natural
processes involving the dynamics of a tumour in mathematical modeling. The
mathematical models considered in this thesis therefore leave out certain aspects
which when considered could give more insights concerning tumour dynamics
and cancer therapy. Human body tissue geometry is highly complex and there-
fore a possible extension of this study would be to consider a higher dimensional
tumour spatial domain, such as 3-dimensional (3D) rather than the 1D and 2D
considered in this thesis. The interaction of the tumour with its macro envi-
ronment, rather than just considering its interior domain, would also be a good
aspect to consider in extending the models in this thesis. This would also give
insights into the dynamics of the cells in the surrounding tissue. Other analytic
techniques, for example, lie-symmetries could be employed in determining solu-
tions to the complex sets of ODEs and PDEs in this thesis. Multistage modeling to
consider all the tumour growth stages, rather than just the avascular stage, is also
a plausible extension of this study to investigate when a certain cancer treatment
would be feasible to give to a cancer patient. Lastly, fitting these models to real
data would make this study more deductive as it would determine how realistic
the models are and ascertain the parameter values that may be required for a
complete cancer treatment. This work may be of use to physicians, clinicians, and
cancer drug developers.
Appendix 1- Errata on chapter 2 and 3
In chapter 2:
• f C/(g1 + T) simulates immune cells proliferation. f and g1 are Michaelis Menten
kinetic parameters derived from experimental results. f in this case relates to the
maximum immune cell concentration reached and g1 may relate to the concentra-
tion at which the immune cells proliferation is half maximal.
• f C/(g3 + T) simulates the chemokine production term. Similarly, f and g3 are
Michaelis Menten kinetic parameters derived from experiments. f in this case may
relate to the maximum chemokine concentration reached and g3 relates to the con-
centration at which the chemokine production is half maximal.
• The term ωIL2.R simulates resting cells activation where ω is the rate of stimulation
of resting cells.







• η1 = g1/T0 and η2 = g2/IL20 .
• The term θ1/(η1 + T) comes from the assumption that the formation of cellular
conjugates C occurs on a time scale of several minutes to a few hours, that is,





• The model (4) is not non-dimensionalized but rather a re-scaled one because some
terms like η2, β2 and θ2 are still dimenaional. This does not however in any way
change any part of the analysis and results.
• The dimesnions of k1 are day−1cells−1cm.
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